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Abstract 
Lymphatic filariasis (LF), a mosquito-borne parasitic disease, is a major cause of disability 
in Bangladesh with an estimated 70 million people at risk of infection and tens of thousands 
suffering from the main clinical conditions. LF is targeted for elimination as part of the Global 
Programme to Eliminate LF (GPELF), which aims to interrupt transmission through mass drug 
administration (MDA) and providing patient care to those affected through morbidity 
management and disability prevention (MMD). Since 2001, the National LF 
Elimination Programme in Bangladesh has successfully scaled up MDA and of interrupted 
transmission. More recently the LF Programme has focussed on MMDP strategies, however 
there were significant gaps in knowledge, little understood about the distribution of disease 
and local communities and health workers. In this context, this research project aimed to 
address the current status of LF disability and its management including i) to examine the 
historical distribution of clinical cases in an endemic district, ii) determine the number and 
prevalence of LF after MDA activities, iii) to determine the knowledge, attitude, practices 
(KAP) of community members and patients and iv) to assess the workload, experience and 
perspectives of community health workers (CHWs) for morbidity control in a highly endemic 
district. 
The descriptive and statistical analysis of historical data in Nilphamari district found that 
cases of lymphoedema were widespread and cases of hydrocoele were more clustered in 
one area of the district. Women were more affected by lymphoedema and men by 
hydrocoele, and older people were more affected by clinical condition and people with more 
advanced disease suffered from more acute attacks. A cluster survey conducted in 
Nilphamari district after MDA activities in 2012, including 1242 people found low prevalence 
of clinical cases LF with very few cases especially in people less than 30 years old and the leg 
being the most affected body part. Women were more affected by lymphoedema and men 
by hydrocoele. A KAP study conducted in the same district demonstrated that community 
members and people affected by LF were aware of the National LF Programme and some 
measures to care for themselves. However, despite good awareness campaign by National 
LF Programme it was revealed that there is practice of some inappropriate and unhygienic 
measures like cutting by fish bones/knife and Jharfoak (A local term meaning traditional 
healing based on people’s belief). A KAP study conducted on CHW revealed that knowledge 
about MDA and morbidity control was impressive before any large scale MMDP activities. 
However, the CHWs expressed that they have too much workload, inadequate training and 
lack of incentives for good practice related to morbidity control.  
These results will help the National Programme better understand the distribution of clinical 
disease and what practices to put in place. Bangladesh is progressing well towards the 
elimination of LF.  At this stage national programme will need to demonstrate that services 
are integrated into health systems for long term sustainable support for patients – as their 
condition are chronic and many individuals will remain affected for many more decades. This 
4 
 
study result will provide guidance on where to focus targeted activities on morbidity control 
and how best to utilize the CHW to integrate. 
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Chapter One 
Literature Review and Thesis Objectives  
 
1. Introduction  
1.1 Lymphatic Filariasis 
Lymphatic filariasis (LF) is a vector-borne parasitic infection and one of the leading causes of 
permanent long-term disability in the world. It is classified as one of the neglected tropical 
diseases (NTDs) by the World Health Organization (WHO), which are a diverse group of 
diseases mainly affecting people living in poverty (WHO, 2013, 2017). It is caused by three 
species of parasitic worms Wuchereria bancrofti, Brugia malayi, and Brugia timori which are 
transmitted to humans by a variety of mosquito species. The majority of infections (~90%) 
are caused by the W. bancrofti parasite.  An estimated 120 million of people in 73 countries 
are infected with at least one of these parasite species, with about 40 million people suffering 
from disabling clinical manifestation such as lymphoedema and hydrocele. In recognition of 
this significant public health problem, the World Health Assembly (WHA) adopted a 
resolution in 1997 (WHA 50.29) and called upon member states to develop national plans  
that would lead to the elimination of LF as a public health problem (WHO 2017).  
 
1.2 Global Programme to Eliminate Lymphatic Filariasis (GPELF) 
The WHO established the Global Programme of Elimination of Lymphatic Filariasis (GPELF) 
with the goal of LF elimination as a public health problem by the year 2020.  To achieve the 
global goal of a two-fold strategy was been taken. First, to interrupt transmission using 
combinations of two medicines delivered to entire population at risk known as mass drug 
administration (MDA). Second, to alleviate suffering of people with the clinical 
manifestations, including lymphoedema and hydrocele, by providing morbidity management 
and disability prevention (MMDP).   
GPELF has been one of the most rapidly expanding public health programmes. In the first 
decade, GPELF saw an extraordinary scale up of activities. GPELF has developed several 
important guidelines in different languages for the endemic countries. Subsequently GPELF 
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identifies the challenges and expanded elimination programmes to achieve full coverage. 
GPELF also developed metrics for monitoring and reporting of programmes.  The elimination 
targets has been achieved in several endemic countries and many more in process of 
validation with the aim to declare elimination (WHO 2012; WER 2017). 
 
1.3 Global geographical distribution of lymphatic Filariasis 
Lymphatic filariasis (LF) is a disabling and disfiguring mosquito-borne parasitic disease, and 
one of the leading causes of permanent long-term disability in the world. It is classified by 
the WHO as one of the NTDs, which are a diverse group of diseases mainly affecting people 
living in poverty (WHO, 2013, 2017). In recognition of significant worldwide burden in 1997, 
WHA called upon Member states to develop national plans that would lead to elimination of 
LF. In 2000, the GPELF was launched with a goal of eliminating LF as a public health problem by 
2020 by interrupting transmission through MDA and addressing patient care through MMDP 
(WHO, 2013; Ramaiah KD et al, 2014). Recent estimates indicate that approximately 1.4 billion 
people living in 73 tropical and sub-tropical countries (WHO-WER, 2011) are at risk of 
infection, with an estimated 16.7 million people potentially affected by lymphoedema (limbs 
and breast swelling) and 19.4 million men by hydrocoele. The geographical and 
environmental limits are estimated in models maps as shown in Figure 2.1.  It has been 
reported that there are 45 countries have lymphoedema and 40 countries have hydrocele 
patients all over the world (WHO-WER 2017). Currently only 34 endemic countries have 
reported MMDP services, shown in Table 1.1 (WHO-WER 2017). 
 
1.4 Lymphatic Filariasis in the South-East Asia Region  
LF is endemic in countries within mainland of South East Asia Region (SEAR). The WHO South 
-East Asia accounts for 55.7% of the at-risk population with 94.6 % of reported lymphoedema 
cases and 85.2% of reported hydrocele cases globally (WHO 2013, WER 2016; Dickson et al, 
2017). Elimination of LF in this geographical area would have a significant impact on the 
global disease burden. Countries with the heaviest burden include India, Bangladesh and 
Indonesia.  LF in the SEAR is caused by W. bancrofti and B. malayi and transmitted mainly by 
Culex quinquefasciatus. Aedes spp. and Mansoniua spp. mosquitoes. 
Overall the SEAR region is progress well despite some challenges. MDA is still required in 5 
countries. Bangladesh and Thailand have stopped MDA nationwide after post-MDA 
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surveillance activities using the Transmission Assessment Survey (TAS) tool (WHO- WER, 
2017). Nepal has stopped MDA in 31 out of 61 endemic districts. The challenge is some 
bordering districts of India where the TAS has failed.  The challenge for India is developing 
strategies to ensure improved compliance with each additional round of MDA (WHO, 2017).  
Overall the lack of reporting of MMDP activities is of concern in the SEAR and there is a focus 
for countries to improve this (WHO, 2017). This may be more readily achieved once National 
programmes finish MDA activities and can then begin to prioritize MMDP services.     
 
1.5 Lymphatic Filariasis in Bangladesh  
Bangladesh, a densely populated country in the SEAR and a major LF endemic country. The 
burden of LF is considered to be immense with the highest rates of infection and an estimated 
70 million people (approximately half the total population) were considered to be at risk of 
LF infection, with tens of thousands of people suffering from various forms of clinical 
presentation, including limb lymphoedema/elephantiasis and hydrocele (Hafiz et al, 2015). 
In Bangladesh, LF is caused by Wuchereria bancrofti and transmitted by Culex mosquitoes 
(WHO, 2014, Ramaiah et al, 2014). The Bangladesh LF Programme was launched in 2001. To 
assess which districts required MDA, the LF Programme took a conservative approach and 
used a combination of the three parameters to select MDA eligibility; i) Mf prevalence, ii) 
antigenaemia (Ag) prevalence, and iii) frequency of clinical cases. Baseline prevalence 
mapping and historical data indicated that the disease was highly endemic in 19 of the 64 
districts and considered eligible for MDA. This was based on the available Ag and Mf rates of 
between 1% and 17% and evidence of clinical cases (Saha et al, 2011, Wolfe et al. 1972). The 
burden was found to be highest in Rangpur Division in the north, where 23% Mf prevalence 
and up to 10% chronic disease have been reported (MOHFW, 2010; Wolfe et al, 1971). A 
further 15 districts were found to be endemic but considered to have low endemicity 
(according to antigen (Ag) tests in 2002-2004) and therefore not considered eligible for MDA.   
The Directorate General of Health Services (DGHS) has been very supportive and committed 
to the LF programme which is managed through the Ministry of Health and Family Welfare 
(MOHFW). Over the past 10-15 years the main focus of the programme has been on scaling 
up MDA activities across the 19 highly endemic districts, which has included extensive social 
mobilization, Information, Education and Communication (IEC) activities and in some recent 
18 
 
years, morbidity control services (WHO, 2000).  The MDA activities have been very successful, 
and all endemic districts are currently under post-MDA surveillance (Shamsuzzaman et al. 
2017). 
The LF Programme has more recently focussed its activities on MMDP and the scale up of 
home-based morbidity control in highly endemic districts. In the northern Rangpur Division, 
the first extensive patient searching was conducted in 2005 with more than 40,000 patients 
found. In selected hospitals, surgeries for men with hydroceles were initiated and some 
home-based care training conducted. Even though data on clinical cases were available, at 
the start of this thesis, the data has not been examined, there had been no recent study 
determining prevalence and severity of recent clinical condition after several rounds of MDA, 
and further little was known about the health workers situation and what support would be 
required to implement a large-scale morbidity control programme.  
1.6 Parasite, vectors and life cycle 
LF is caused by nematodes (roundworms) that inhabit the lymphatic vessels and lymph nodes 
of a human host. Wuchereria bancrofti, Brugia malayi and Brugia timori cause lymphatic 
filariasis. Part of their life cycle is in vector mosquito. Female mosquito transmitted among 
human while taking their blood meals. Among the mosquito Anopheles, Culex, Mansonia , 
Aedes species are habitat in different areas. In Bangladesh, the most common parasite is 
Wuchereria bancrofti (Ramaiah, et al., 2011). The following Table 2.2 shows the periodicity 
and distribution and main vectors of different parasite causing LF (WHO, 2016). 
Table 1.1 Periodicity and distribution of organisms that cause human lymphatic filariasis  
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(Source WHO, 2013). 
 
Figure 1.1 Microfilaria of Wuchereria bancrofti 
 
 
 
                    Source Parasitology  
Figure 1.2 Life cycle of Wuchereria bancrofti 
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 “During a blood meal, an infected mosquito introduces third-stage filarial larvae onto the skin of the human host, 
where they penetrate into the bite wound . They develop in adults that commonly reside in the lymphatics 
. The female worms measure 80 to 100 mm in length and 0.24 to 0.30 mm in diameter, while the males measure 
about 40 mm by .1 mm. Adults produce microfilariae measuring 244 to 296 μm by 7.5 to 10 μm, which are 
sheathed and have nocturnal periodicity, except the South Pacific microfilariae which have the absence of marked 
periodicity. The microfilariae migrate into lymph and blood channels moving actively through lymph and blood 
(Figure 1.1) . A mosquito ingests the microfilariae during a blood meal . After ingestion, the microfilariae 
lose their sheaths and some of them work their way through the wall of the proventriculus and cardiac portion of 
the mosquito's midgut and reach the thoracic muscles . There the microfilariae develop into first-stage larvae 
(L1)   and subsequently into a second stage (L2) and then third-stage infective larvae (L3) . The third-stage 
infective larvae (L3) migrate through the hemocoel to the mosquito's prosbocis  and can infect another human 
when the mosquito takes a blood meal .” (Figure 1.2) 
Source: Centers for Disease Control (CDC) 
https://www.cdc.gov/parasites/lymphaticfilariasis/biology_w_bancrofti.html  
 
 
1.7 Pathogenesis of LF 
The disease develops as a result of the infective larvae (L3) deposited on the skin of the 
human host, where it penetrates the skin, and then enters the bloodstream and lymphatics 
and where they develop into adult worms. One main site for adult parasites to develop is the 
scrotal lymphatics in men or boys after puberty, and these can be seen by ultrasonography 
known as 'filarial dance sign' (Noroes et al. 1996; Dreyer et al 1999). Other common sites are 
in the larger lymph vessels and lymph nodes draining to lower and upper limbs, and 
commonly seen in women (Mand et al, 2004; Fox LM et al, 2005). Adult worms can be 
detected by Doppler sonography in the lymphatics of the inguinal and axillary regions 
(Shenoy RK et al, 2007). The adult parasites live in these human body sites for long time; 6-8 
years or more, and are responsible for initiating the early pathology in host (Drayer et al, 
2000). 
The earliest structural change is the dilation of lymph vessels where the adult worms live. 
This has been demonstrated in subjects who are clinically asymptomatic except for presence 
of microfilariae (mf) in blood, by ultrasound examination of the lymphatics of the spermatic 
cord; lymphoscintigraphy of the limbs and by direct examination of lymph vessels resected 
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by surgery (Noroes et al, 1996). Dilatation of the lymph vessels has been demonstrated by 
lymphoscintigraphy (Shenoy et al, 2007). It is believed that this damage to lymph vessels is 
caused by the adult parasites through chemicals from them, causing vessel dilatation or 
inhibit contractility (Gyapong et al, 2005). Over time this pathology results in dysfunction. It 
is noted that during this early stage of LF infection, the host having the adult parasites does 
not have any evidence of clinical manifestation and this phase is known as asymptomatic 
microfilaremia. It has been reported that once established this lymphatic pathology is 
irreversible even after treatment or death of the filarial parasite and promotes progression 
of LF disease (Freedman et al, 1994). 
Once this lymphatic damage progresses, stasis of lymph tends to occur in the dilated vessels 
due to incompetence of the unidirectional valves in them. This damage is aggravated by 
bacterial infections of the limb, prolonged standing or strenuous exertion. The transient 
lympho-paralysis that sets in during acute bacterial infections also abets the lymph stasis. 
Stagnation of lymph encourages growth of bacteria invading the region. Any interference 
with the skin integrity of the affected region like injuries, fungal or bacterial infections, 
fissuring of the skin, and paronychia or eczema favour entry of pathogenic bacteria into the 
tissues infection (Shenoy et al, 1999). These bacteria, mainly streptococci and occasionally 
other pathogens, are responsible for the acute attacks of dermato-lymphangio-adenitis 
(ADLA) commonly seen in filarial limbs (Shenoy et al, 2007). Bacteria have been cultured from 
the skin and lymph from the oedematous limb (Olszewski  et al, 1997; Olszewski , 1994). 
 
1.8 Diagnosis and diagnostic tools  
There are several methods for diagnosis if LF infection. Detection of Mf by direct or thick film 
techniques was used traditionally. Where LF is nocturnally periodic thick blood smear is 
completed at night corresponding to the time of maximum mf density. This test is superseded 
by highly sensitive and more convenient antigen and antibody-based tests (Dickson, 2017). 
 
Detection of antigen test include immunochromatographic card test (ICT) and Og4C3 
enzyme- linked immunosorbent assays (ELISA).  ICT test result is shown in figure 1.3. This test 
uses monoclonal antibodies to detect secretory-excretory antigens produced by adult filaria 
(Weil  et al., 1987; Weil et al.,1997). As antigen is produced in different stage of life, antigen 
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test is two to five-fold more sensitive that thick smear test. It can be done at day time. Og4C3 
has higher sensitivity than ICT but they are less practical in the field (Gass et al, 2012).             
   
Antibody based tests detect IgG4 antibodies against Bm14 antigen (B. malayi and W. 
Bancrofti) or BmRI (B. malayi only). It is highly sensitive and specific, but it cannot prove 
current infection as antibody remain elevated for many years after infection. Interpretation 
is shown in figure 1.4. Less commonly antibody in urine can be tested. However, urine 
antibody is less sensitive than blood based antibody and are not available commercially. PCR 
assays to detect LF DNA in humans may be used to diagnose LF. It is not used in endemic 
countries as it needs advanced laboratory facilities but it is more sensitive than other tests 
(Gass et al, 2012, Rebolo  et al, 2014). 
 
 
 
Figure 1.3 Showing ICT test interpretation  
 
(Source WHO training module)  
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Figure 1.4 Showing Brugia rapid test interpretation  
 
 
 (Source-WHO MMDP, 2013) 
 
 
1.9 Clinical symptoms 
The main manifestations of LF disease include i) lymphoedema, with more severe cases known 
as elephantiasis, defined as advanced stage disease based on Dreyer staging and ii) hydrocoele 
in men. Many LF patients also suffer from acute infections described above i.e. ADLAs or acute 
attacks, which can be very painful and disabling (WHO, 2013).  The photos in Figure 1.5 show 
the clinical conditions as presented by the WHO on their main LF website (WHO 2017). 
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Figure 1.5 Clinical manifestation of LF  
 
 
 
        (Source WHO-MMDP, 2017) 
 
Acute Dermatolymphangioadenitis (ADLA) is acute Inflammation of the skin, lymph vessels 
and lymph glands, resembles erysipelas or cellulitis. It is characterized by local pain and 
swelling and with fever and chills (WHO, 2013). Acute attack of ADLA precipitates 
lymphedema for the first time in an affected limb, usually starting in childhood. Such 
repeated attacks later perpetuate and worsen the lymphedema leading to elephantiasis. Lack 
of local hygiene favours more such attacks and a vicious cycle is thus established (Shenoy RK 
et al, 1998)]. Advanced stages of lymphedema are characterized by increasing dilation and 
tortuosity of the lymphatics, endothelial proliferation, formation of new lymph channels, and 
obstructive changes and dermatosclerosis with nodular and warty changes. Some study 
showed positive correlations between the Dreyer stage of the worse leg and i) number of 
episodes of ADLA, ii) number of interdigital lesions, and iii) number of abnormal nails 
(McPherson et al, 2006) 
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Lymphoedema 
 lymphoedema is a condition of localized fluid retention and tissue swelling caused by a 
compromised lymphatic system, which normally returns interstitial fluid to the thoracic duct, 
then the bloodstream (WHO, 2013). LF is one of the important causes of lymphoedema of 
limbs in tropical countries.  
Lymphoedema and its more advanced form elephantiasis, occur primarily in the lower limbs. 
May be in upper limb, breast and genitalia less frequently. It is commoner in females. 
Progression of lymphoedema has been implicated by several factors. Repeated episodes of 
ADLA is one important factors. Obviously its most advanced form of diseases, elephantiasis 
may prevent people from carrying out their normal activities.  Although filarial lymphoedema 
is distinguished from condition such as heart failure, malnutrition, venous disease, 
podoconiosis and HIV/AIDS associated Kaposi’s sarcoma, there is no agreement on its 
classification. However, Stemmer’s sign (Figure 1.6) is a diagnostic sign of lymphoedema. A 
positive Stemmer’s sign is inability to pinch a skin fold of skin at the base of the toes. 
Podoconiosis, known as non filarial lymphoedema is prevalent in highland tropical areas of 
Africa, Central America and north-west India where there is commonly a high seasonal 
rainfall. has similar consequences of lymphoedema, It is also considered as NTD and requires 
same management for LF lymphoedema (Kebede el al, 2018). Podoconiosis are neglected 
tropical diseases (NTDs) that pose a significant physical, social and economic burden to 
endemic communities. Patients affected by the clinical conditions of LF (lymphoedema and 
hydrocoele) and podoconiosis (lymphoedema) need access to morbidity management and 
disability prevention (MMDP) services. It is often termed “non-filarial” lymphoedema, and 
can be generally clinically distinguished from LF lymphoedema by its ascending progression 
of disease (rather than descending), and by being most commonly bilateral, as compared 
with LF which is most commonly descending and unilateral (Kebede el al, 2018). 
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Figure 1.6 Stemmer’s sign is a diagnostic sign of lymphoedema 
                              
 Figure 1.7 Difference between normal and lymphoedema leg  
 
 
 
 
 
(Source Medscape, 2017). 
 
Stages of lymphoedema 
 
Based on severity different stages and graded was done. WHO defined following stages 
(Figure 1.8) are widely accepted for morbidity management. The seven stages are as follows 
Stage 1: Lymphoedema reversible overnight; 
Stage 2: Irreversible lymphoedema with normal skin; 
Stage 3: Irreversible lymphoedema with thickened skin and shallow folds whose 
base is visible; 
Stage 4: Irreversible lymphoedema with knobs (bumps and lump); 
Stage 5: Irreversible lymphoedema with deep folds whose base is visible when 
separated by finger; 
Stage 6: Irreversible lymphoedema with mossy foot; 
Stage 7: With irreversible lymphoedema, disability to do routine activities adequately 
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Figure 1.8 Stages of lymphoedema 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Source Dreyer et al, 2000) 
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Hydrocele 
A hydrocele is a type of swelling in the scrotum that occurs when fluid collects in the thin 
sheath surrounding a testicle (Figure 1.9). Boys and adult men can develop a hydrocele due 
to inflammation or injury. LF is one of the common cause in tropical countries (WHO, MMDP 
2013). 
 
Figure 1.9 Difference between normal scrotum and hydrocele 
 
 
 (Source Mayo foundation for medical education and research) 
 
Historically the size of the hydrocele has been described as to the one of a tennis ball and 
used it as a criterion for repartition of the cases in two categories only: lesser or greater than 
a tennis ball. Such enlargement of the scrotum described as “monstrous” by an observer, will 
be only the size of a “big orange” (or papaya) for another observer who will distinguish it 
from a “small” or “medium orange” (or papaya), which is not more accurate (Capuano & 
Capuano, 2011). 
1) Type of hydrocele 
Unilateral or bilateral. 
2) Side of hydrocele 
Right or left side of the scrotum  
3) Size of hydrocele 
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Hydroceles were classified according to their size into six stages By Capuano, 2011 (Figure 
1.10).  
 
The stages are recorded in roman numerals. 
 
• Stage I: The size of the scrotum is less than that of a tennis ball.  
• Stage II: The size of the scrotum is greater than that of a tennis ball up and down; the lower 
pole of the scrotum does not reach halfway up the thigh (between the lower edge of the 
great trochanter and the top edge of the knee identified by the upper edge of the patella).  
• Stage III: The lower pole of the scrotum goes down to mid-thigh and reaches the area 
between mid-thigh and the knee (upper edge of the patella).  
• Stage IV: The lower pole of the scrotum reaches the area between the upper edge of the 
patella and the lower edge of the knee (tibial tuberosity).  
• Stage V: The lower pole of the scrotum reaches the area between the lower edge of the 
knee (tibial tuberosity) and mid-leg. 
• Stage VI: The lower pole of the scrotum reaches the area between mid-leg and the ankle 
(bi-malleolar line).  
 
4) Burial of the penis 
The burial of the penis, which often accompanies hydroceles, can be assessed on the patient 
standing or lying down. The burial was classified according to its importance, in five 
categories or Grades from zero to four recorded in arabic numerals: 
• Grade 0: no apparent burial, the length of the penis is within normal limits 
• Grade 1: partial burial, the length of the visible part of the penis is more than 2cm.  
• Grade 2: more important partial burial, the length of the visible part of the penis is less than 
2cm.  
• Grade 3: total burial of the penis. The prepuce, or the tip of the glans penis if the patient is 
circumcised, is visible and flush with the surface of the scrotum  
• Grade 4: total burial of the glans penis which is invisible, the burial cannot be reduced and 
causes micturition problems  
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Figure 1.10 Staging of Hydrocele 
 
 
 
Stage I                                       Stage II                           Stage III 
 
 
 
 
 Stage IV                                            Stages V and VI 
 
(Source-Capuano & Capuano, 2011). 
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Management of Hydrocele 
Figure 1.11 Flowchart of management of hydrocele (Source; WHO MMDP, 2013) 
 
 
Treatment: excision of hydrocele (Capuano G.P.& Capuano C, 2011). 
➢ Type of anaesthesia: spinal anaesthesia or general anaesthesia (complicated). 
Surgical procedure included following steps 
The fasting patients were hospitalized the day before or the morning of the surgery for 
clinical, biological and electro-cardio graphic assessment and usual preparation (shaving of 
the designated surgical area, shower). 
All hydroceles were treated by total vaginectomy using the following technique: 
➢ Access: anterolateral right (for unilateral right hydrocele) or anterolateral left (for 
unilateral left 
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➢ hydrocele) or anterolateral right and left separately (for bilateral hydrocele). 
➢ Section of the different layers under the scrotum with the electrocautery knife 
accompanied by a step-by-step electrocautery for perfect haemostasis. 
➢ Identification of the spermatic cord as high as possible to the root of the scrotum 
and isolation. 
➢ Externalization of the mass after complete dissection by fingers, electrocautery 
knife and Metzenbaum scissors. 
➢  Fluid sample taking by needle and syringe for the laboratory. 
➢ Content emptying by electric suction. 
➢ Complete vertical opening of the vaginalis on its front side by electrocautery knife 
from the drain suction hole to the lower pole at the level of the handle of the 
deferent and then up until the cord. 
➢ Inventory and examination of the testis and epididymis 
➢ Removal of related lesions by electrocautery knife: hydatids, cysts of the head or of 
the tail of the 
epididymis. Complete resection of the parietal layer of the tunica vaginalis by 
electrocautery knife as close as possible to the path of its continuation as the 
visceral layer. Haemostatic cuticular suture on the cut margin on the periphery of 
the testes using absorbable sutures 000. 
➢ Fixation of the testis to the lower pole of the scrotum (or the neo-scrotum if the 
patient had a scrotal reduction by plasty, see below). 
➢ Closing in two layers on Delbet drain (corrugated rubber blade) 
➢ Use of non-absorbable sutures for ligatures and suture of the deep layers and of 
the skin in a second time. 
 
In a few cases the importance of the excessive scrotum after treatment of the hydrocele 
justified a reduction by plasty. Similarly, in some instances the burial of the penis was not 
spontaneously reduced during the operation and a surgical reduction was performed. Both 
procedures were made using surgeon’s own techniques.  
postoperative dressing and follow up 
Complementary treatment: excision of epididymal cysts, hydatids or other associated 
conditions discovered during the surgical treatment of the hydrocele; 
➢ Treatment of the scrotum: by simple closure or by personal technique of scrotal 
reduction by plasty. 
➢ Reduction of a burial of the penis: spontaneous during surgery or by surgical 
treatment; epididymal cysts, hydatids or other associated conditions 
discovered during the surgical treatment of the 
➢ hydrocele; 
➢ Treatment of the scrotum: by simple closure or by personal technique of scrotal 
reduction by plasty. 
➢ Reduction of a burial of the penis: spontaneous during (Capuano G.P.& 
Capuano C, 2011). 
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Available medications can kill some species of filarial parasites, but they cannot 
reverse advanced clinical manifestations of filarial infections such as blindness or 
elephantiasis. On the other hand, simple methods have been developed for lymphoedema 
management that reduce the frequency of filarial fever attacks and often lead to significant 
improvement in patients with severe lymphoedema or elephantiasis (Mend et al, 2012). 
 
Most filarial parasite species contain intracellular bacteria called Wolbachia that are required 
for parasite development and reproduction. Antibiotic treatments that clear Wolbachia can 
sterilize and eventually kill adult filarial worms that contain Wolbachia (Taylor t al., 2005). 
 
Large-scale programmes are using donated drugs to control and, in some cases, actually 
eliminate onchocerciasis and lymphatic filariasis in many disease-endemic countries. In the 
short term, mass drug administration programmes cure infections and prevent disease. 
However, the long-term goal of these programmes is global elimination of onchocerciasis and 
lymphatic filariasis. 
 
Doxycycline has been identified as an anti-morbidity drug for the treatment of filariasis 
(elephantiasis) (Taylor t al., 2005). On study shows minocycline is superior than doxycycline 
regimen as anti-Wolbachia microfilariae (Sharma et al, 2016). Mand, et al.,2012 has 
demonstrated Doxycycline improves filarial lymphedema independent of active filarial 
infection in a randomized controlled trial. 
 
Morbidity management and disability prevention (MMDP) in lymphatic filariasis 
WHO suggested basic management of lymphoedema involves simple measures, which can 
usually be carried out by the patient. The complete set of measures is more complex but 
usually cannot be implemented in resource poor settings. Where there is comprehensive 
health system, health workers could promote use of complete package including 
compression or pressure bandages, lymphatic massage and other recognised methods. 
Traditional health workers like CHWs should be involved in management wherever possible 
(WHO-MMDP, 2013). 
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Community home-based prevention 
Lymphoedema is the main problem in filariasis. It mostly worsens due to negligence in the 
initial treatment. Once lymphoedema develops, it cannot revert to normal condition after 
certain stage. 
But encouragingly, it also does not deteriorate if regular self-care is adopted. A deranged 
lymphatic system lowers the resistance to infection. If it is infected repeatedly, the condition 
worsens, and it becomes a source of constant suffering. Hygiene of the part prevents 
infection by fungus and bacteria. If regular care is taken at home, acute attacks are prevented 
to a great extent. Care of an affected part needs to be taken almost throughout life, often 
assisted by family and community. 
The important prerequisite for community home-based care is to entrust a person, either 
from family, friends or community, apart from the LF sufferer, to assist and monitor the 
home-based care.  The affected part needs to be observed keenly to detect the points/sites 
of the entry lesions regularly, especially the inter-digital spaces and the skin folds. The 
following are the key components: 
 
Figure 1.12 Measures for managing lymphoedema (Source; WHO MMDP, 2013) 
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Figure 1.13 Flowchart of management of Lymphoedema  
(Source; WHO MMDP, 2013) 
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Figure 1.14 Flowchart of management of Lymphoedema cont’d  
 
 
(Source; WHO MMDP, 2013) 
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Washing: The affected parts should be washed with soap and water twice daily at room 
temperature and dried carefully with a clean cotton clothes and gauze. Cleaning should be 
gentle, without rubbing. Special attention should be paid to the toe web spaces. Diligent 
washings may reduce the requirement of antibiotics and prevent progression of 
lymphoedema.  
Figure 1.15 Skin care and washing (Training module, 2012) 
 
 
Skin care: An intact skin provides an effective barrier against infection. Wearing 
shoes/sandals is a strategy to protect skin. In the presence of bad odor or infection potassium 
permanganate or other antibiotics is added in water. Use of turpentine oil removes maggots. 
In case of fungal and bacterial infection appropriate ointment should be applied. 
 
Exercise: The affected limb should be raised at night and daytime whenever possible and 
exercise regularly with low intensity movement of the joints. The patients should be 
encouraged to move as immobility worsen the condition significantly. 
Simple exercises help in lymph flow. The following exercises can be carried out in any place 
and at any time. 
➢  Rising up and down on toes - this exercise can be done standing or sitting. 
➢ Flexing the foot upwards and making circular movements at the ankle joint.  
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Figure 1.16 Exercise (Training module, 2012) 
 
 
In case of acute attack, exercise should be avoided. 
 
Elevation: Elevation is a simple measure which lessens the suffering due to lymphoedema. It 
enhances lymph flow from the affected part and enables the affected person to carry out 
daily activities with more comfort. Elevation can be done by: 
➢ placing a pillow under the mattress or bricks under the cot while sleeping; 
➢ placing a pillow or a folded blanket under affected breast, arm or scrotum; 
➢ placing the affected leg on some support at the level of the waist during 
cooking, playing, working, breastfeeding and so on. 
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Figure 1.17 Elevation (Training module, 2012) 
 
 
 
Foot care: Suitable footwear is essential to protect, keep the foot clean and prevent entry 
lesions. The swelling being on the dorsal side of the foot and irregular, special modification 
is essential in designing suitable footwear. It is important to select the right footwear in the 
right size, because poorly fitted ones can cause more harm than good. Footwear should keep 
the feet in place while walking, and not be tight. Footwear needs to be prepared only by an 
experienced shoe technician. The criteria for good footwear are as follows: 
➢ It should fit like gloves but should not be too tight or too loose. 
➢ It should not slip at the heel and there should be plenty of space at the toes. 
➢ It should not have heels and iron material; nails are not to be used in its 
manufacture. 
➢ Upper straps should be of nylon (woven straps), 1 or 2 inches wide and 
adjustable (WHO-MMDP, 2013) 
➢ It should not slip at the heel and there should be plenty of space at the toes 
➢ It should not have heels and iron material; nails are not to be used in its 
manufacture. 
➢ Upper straps should be of nylon (woven straps), 1 or 2 inches wide and 
adjustable (WHO-MMDP, 2013) 
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Figure 1.18 Flowchart of management of ADLA on Lymphoedema (Source: WHO MMDP, 
2013) 
 
During acute attacks, affected persons are advised not to: 
➢ exercise (it can be very painful); 
➢ put anything which is warm or hot on the skin; 
➢ open or slit a blister; 
➢ cut the skin for any reason; 
➢ bandage the leg; 
➢ apply herbs, ashes, or anything else on the skin that has not been advised by 
a doctor or nurse. 
A person with acute attack should be referred to the health facility if antibiotics or other 
measures fail to relieve the symptoms within 24 hours, or if the acute symptoms increase 
(Figure 1.18, WHO-MMDP, 2013) 
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Figure 1.19 Management of lymphoedema as per stages (Source; WHO MMDP, 2013) 
 
 
 
Socioeconomic burden 
Lymphoedema and hydrocele lead to permanent disability. They often cause disfigurement 
and long term disability (WHO, 2013). Managing acute condition is a burden on patients and 
health system. Economic losses due to reduced productivity are also a drain on economy. It 
was estimataed to be responsible for losses of US$ 60-85 million per year in India (Suma TK 
et al, 2002; Shenoy RK et al, 2003) and US $ 38 million per year in the Philippines Weekly 
Epidemiological Record-WHO, 2004).  
Chronic condition exerts a heavy social burden on patients. Lyphoedema specilay 
elephantiasis considered shameful and prevent from playing their role in society and 
stopping working or changing to less productive jobs. All these  badly effect on quality of life. 
Lynn”s paper on disability demonstrated the several factors affecting the quality of life in LF 
patients (Zeldenryk L et al 2013). 
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Figure 1.20 Assessment tools in different stages of elimination 
 
 
  
 
Global Programme to Eliminate Lymphatic Filariasis (GPELF) 
In 1997, the World Health Assembly resolved to eliminate lymphatic filariasis as a public 
health problem (WHA resolution 50.29). In 2000, the GPELF was launched by WHO 
 
Goal: Global elimination by 2020 
Aim 1. Stop the spread of infection: interrupt transmission by MDA 
Aim 2. Reduce the suffering caused by the disease: morbidity management and disability 
prevention-MMDP 
 
GPELF recommends MDA using a combination of medicines: 
1. diethylcarbamazine (DEC) + albendazole (in countries not co-
endemic for onchocerciasis) 
2. ivermectin + albendazole (in countries co-endemic for 
onchocerciasis) 
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➢ of single-dose treatment for at least 5 years 
➢ to all eligible individuals in the entire endemic area 
 
LF also has the ability to link with other control strategies including MDA, vector control using 
insecticide treated nets (ITNs) and also for morbidity management. The following figure 1.21 
highlights opportunities for integrating LF activities into programmes of other disease.  
 
Figure 1.21 Overlapping strategies of elimination and control of NTD 
 
  
(Source: WHO-MMDP, 2013). 
 
1.10. Achievement towards elimination of LF 
LF is second leading cause of permanent disability worldwide and accounts for 2.8 million 
disability adjusted life years (DALY) lost (Dickson et al, 2017). WHO recommends that all LF 
endemic countries be part of the proposed strategy that aims to reach the elimination goal 
by 2020. Between the beginning of GPELF in 2000 and 2012, 59 countries have started 
implementing MDA, and 12 countries have successfully stopped MDA after five or more 
rounds with high coverage and entered the post-MDA surveillance phase (Ichimori et al, 
2014). Of the remaining countries, all 14 will implement and complete LF mapping by the end 
of 2015. Initially GPELF’s main focus was MDA implementation and achieving successes 
towards elimination. The MDA coverage of total population requiring MDA was 57.9% with 
495.6 million persons in 40 reporting countries, in 2016 (WHO-WER, 2017). Figure 1.22 shows 
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region wise MDA status reported to WHO. After successful five or more rounds of MDA, 
Transmission Assessment Survey (TAS) was conducted. In 2016 TAS was implemented in 23 
countries with an overall pass rate of 91.9%. Area wise WHO reported TAS result is shown in 
figure 1.23 (WHO-WER, 2017). In those countries no longer MDA is needed. On the other 
hand, a failed TAS means persistent transmission after MDA. American Samoa, India, 
Malaysia, Myanmer, Philippines and United Republic of Tanzania experienced failed TAS in 
2016.  
Figure 1.22 Global environmental suitability (A) and (B) limits of LF transmission  
 
 
 
Source: Cano et al. 2014 
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Table 1.2 Summary of morbidity management and disability prevention data reported to 
WHO (Source, WHO-WER, 2017) 
 
 
Figure 1.23 Progress of preventive chemotherapy by target disease for the 2008-2016 
(WHO-WER, 2017). 
 
 
 
In African Region, Togo is the first country to eliminate LF as a public health problem. 9 other 
countries in the region also passed TAS. In South East Asian region, Bangladesh has stopped 
MDA and joined Thailand for post MDA surveillance. Maldives and Sri Lanka continued post-
validation surveillance (WHO-WER, 2017). In Eastern Mediterranean Region, Egypt and 
Yemen no longer require MDA and implemented and passed TAS. Two countries of Western 
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Pacific Region, Marshall Islands and Tonga were acknowledged for achieving elimination of 
LF as a public health problem (WHO-WER, 2017). 
Figure 1.24 Cumulative implementation units that have completed transmission 
assessment survey and no longer require MDA (WHO-WER, 2017)  
 
 
 LF in South East Asia  
The global burden of LF is highest in SEAR, representing more than half of the people at risk. 
The main parasite is W. bancrofti may be treated with MDA using the drugs albendazole in 
combination DEC, to clear the microfilaria in the blood of human populations. In 2015, the 
WHO reported that 50 countries have started to implement MDA, indicating significant 
progress, especially in SEAR (WHO-WER 2015). More recently, the WHO with regional 
partners and donors have focussed on patient care and started the scale up of MMDP. 
Countries are encouraged to conduct situation analyses to better establish the burden of 
disease and assess how to implement quality and access to care and services for LF patients 
(WHO, 2017; Ichimori  et al, 2014, WHO 2013). This MMDP work complements the MDA work 
and will help to treat the lymphoedema, elephantiasis, and/or hydrocoele of affected 
individuals. It is also an important component of eliminating LF as a public-health problem 
and part of the WHO validation of elimination dossier requirements (Weil et al, 1997). 
 
47 
 
Figure 1.25  LF endemic countries in South East Asian region (WHO, 2017) 
 
 
1.11 LF Elimination in Bangladesh 
Bangladesh with an estimated population of 142.30 million (Census 2011), is a major LF 
endemic country. The burden of LF is considered to be immense with the highest rates of 
infection and an estimated 70 million people (approximately half the total population) were 
considered to be at risk of LF infection, with tens of thousands of people suffering from 
various forms of clinical presentation, including limb lymphoedema/elephantiasis and 
hydrocele (Hafiz et al, 2015). 
The disease is caused by the parasite Wuchereria bancrofti and Culex mosquitoes are the 
main vectors for transmission (WHO, 2014, Ramaiah et al, 2014). In 2001, an assessment 
based on microfilaria (Mf) levels found the disease to be prevalent in 34 of the 64 districts 
with 19 districts eligible for mass drug administration (MDA). The remaining 15 districts were 
found very low endemic (according to Ag test in 2002-2004) and not eligible for MDA 
according to Mf survey, as Mf prevalence is below 1 (figure 1.25).  The highest LF endemicity 
occurs in the northern region of the country where during the 1970s–1980s, and at the start 
of the LF Programme, estimates of microfilaria prevalence were up to 17% with disease 
burden 10%. Nilphamari District is considered to have the highest levels of endemicity. Figure 
1.25A shows the endemic status of the districts in Bangladesh.   
Bangladesh 
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Figure 1.26 LF in Bangladesh at baseline and recent period. 
 
 
 
Source: Shamsuzzaman et al, 2017. 
 
Over the past 16 years, the LF Programme in Bangladesh has concentrated its efforts on 
interrupting transmission through annual MDA with the two drugs albendazole and DEC. 
These programmatic efforts have been very successful as measured by the TAS, following the 
WHO post-MDA surveillance guidelines (Figure 2.27B shows the TAS status in 2015).  
However, a large number of cases with chronic clinical manifestations remain (WHO, 2011; 
Hafiz et al, 2012). Bangladesh was one of the first countries in the SEAR to start the 
elimination process with MDA to interrupt transmission in endemic areas (WHO, 2014, 
Ramaiah et al, 2014) and one of the first countries to begin the elimination verification 
process (Addiss et, al. 2007; Brady et al, 2014).  
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National LF Elimination Programme Management team in Bangladesh 
Bangladesh LF elimination programme is led by the Director Communicable Disease Control 
(CDC) under Ministry of Health and Family Welfare (MOHFW) with supervision of Directorate 
General of Health Services. The LF Program Manager is responsible for implementation of 
activities related to MDA and MMDP activities. In LF programme team there are three 
medical officers, three consultants, two /three lab technologists, one accountant, two admin 
staff, three supporting staff has been working for implementation and monitoring of 
program.  
International partners provide funding and technical assistance for activities related to 
training, monitoring, sentinel site surveys and dossier development.  At the community level, 
CHWs under supervision of Upazila Health Manager are working for MDA implementation 
and monitoring, MMDP. They conduct home-based morbidity control and provide health 
care through community clinic. In addition, the Japanese organisation, JICA, provide 
assistance through volunteers who are working in highly endemic district for morbidity 
control. They helped to conducted a patient searching survey in 2005 to find out clinical cases 
in the most endemic areas of the northern region of the country.  
Along with Government of Bangladesh, international partners including CNTD-LSTM, UK, 
GPELF, WHO, World bank, JICA, UASID through RTI have been providing technical and 
financial support for LF elimination programme. 
 
1.12 Rationale for the study   
Morbidity control is one of the two main pillars of the GPELF and at the 6th Global GPELF 
meeting in 2010, morbidity control was identified as a research priority (WHO, 2000, 2012, 
2017, Bockarie et. al, 2002). The National LF Elimination Programme in Bangladesh has 
started to address issues related to LF morbidity control on a larger scale to reduce the 
suffering of the huge number of patients (Shamsuzzaman et al, 2017). However, until 
recently very little was known about the burden of disease following MDA, how morbidity 
was being managed, the most appropriate methods to treat disabled communities, and how 
local health workers can facilitate the best care for patients.  
To design the morbidity control services a mapping survey and knowledge, attitude and 
practice (KAP) study on morbidity management practices at community level may play 
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significant role. Mapping is very important to provide policy direction for advocacy and 
program planning on morbidity (Mathieu et al., 2008). Understanding the range of different 
interventions for home-based morbidity control program of lymphoedema will provide the 
information on the most appropriate approach for morbidity control in Bangladesh. Related 
studies may also help to demonstrate how to scale-up morbidity control program, how to 
target high risk groups and specific techniques to help decrease physical and emotional 
burden of the disease and improve quality of life. 
In this context, this research aimed to assess the distribution and severity of disease, 
specifically examining existing data and assessing communities after 5 rounds of MDA in a 
highly endemic district. Further, it aimed to determine patient’s and community health 
workers (CHW) ’ KAP of LF and morbidity management.  The results of the study are expected 
to help plan morbidity control of LF patients and will provide policy direction for advocacy 
and programme planning in Bangladesh. The aim and objectives of the study were discussed 
with National Programme Manager, and were aligned with local control aims, as well as those 
set out internationally by GPELF.  
 
1.13 Overall Aims and Objectives   
The overall aim of the study was to investigate LF distribution and MMDP related activities 
in Bangladesh. The specific objectives related to the research chapters include  
1. To examine the historical distribution of LF clinical case data in an endemic district 
before the scale up of MDA activities 
2. To determine the number of LF clinical cases in an endemic district after a decade of 
MDA activities 
3. To determine the KAP of LF and morbidity management among community members 
4. To assess the workload, experiences and perspective of CHWs before the scale up of 
MMDP activities  
 
1.14 Thesis layout  
Chapter 1. Provides an overview of LF, GPELF, the SEAR, Bangladesh as well as the rational 
for the thesis topic, and outlines the overall aim and specific objectives and thesis layout. 
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Chapter 2. Provides background to the current literature including the global distribution, 
GPELF achievements, the life cycle, diagnostic tools, pathogenesis, clinical symptoms, 
MMDP, socioeconomic burden, LF in SEAR and Bangladesh 
Chapter 3. Examines historical data on LF clinical cases in the endemic district of Nilphamari 
where data on the age, sex, sub-districts level (union, upazila) and clinical condition 
(lymphoedema, hydrocoele, ADLAs) was available 
Chapter 4. Determines the current estimate of clinical disease through a cluster survey in 
Nilphamari district, with data collected on age, sex, sub-districts level (village, union, upazila) 
and clinical condition (lymphoedema, hydrocoele, ADLAs).  
Chapter 5. Determines the KAP of community members and people affected by LF and 
through a field survey in Nilphamari districts which included socio-demographic information, 
and topics including knowledge of filariasis, knowledge of treatment and prevention, opinions 
on transmission and elimination and clinical management and impact. 
Chapter 6. Assesses the CHW workload, experiences and perspectives through a field survey 
in Nilphamari district which included information on demographic and workload 
characteristics, knowledge of disease, prevention and morbidity management, opinions of 
training, morbidity management and programmatic activities. 
Chapter 7. Provides a general discussion and set of recommendation related to the research 
chapters that may be used by the National Programme or researchers interested in 
conducting research in Bangladesh on LF morbidity in the future   
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Chapter Two 
 
Distribution of lymphatic filariasis morbidity cases in 
Nilphamari district before scale up of MDA 
 
2.1 Introduction 
Lymphatic Filariasis is one of the major cause of disability in northern districts of Bangladesh. 
At the very beginning of the LF programme in 1970-80s, estimates of Mf prevalence were up 
to 17% with disease burden 10% (Wolfe et al. 1972; Barry et al. 1971). Nilphamari district is 
considered to have one of the highest levels of endemicity. There was an effective effort to 
estimates LF cases by the Japanese International Cooperation (JICA) volunteers in 
collaboration with the LF programme in 2005. A house to house clinical case identification 
survey conducted and found thousands of cases (unpublished data) who required care. 
Understanding the burden of disease is important as it may help MDA compliance and raise 
awareness of community burden. The data collected by JICA provides an opportunity to examine 
the pre-MDA distribution of clinical cases. 
The main aim of this chapter was to examine the historical distribution of LF clinical cases in 
Nilphamari to better understand the burden of disease before the scale-up of MDA. 
 
2.2. Methods 
2.2.1 Study area  
The JICA survey was conducted in Nilphamari District, which is historically known as highly 
endemic district. The Japanese overseas volunteers worked in this area and they collected 
data from the community under the guidance of National LF elimination programme. This 
district is approximately 1550 square kilometres in size, and bordered by India in north and 
the Bangladesh districts of Rangpur, Lalmonirhat, Dinajpur and Panchagarh in the east, west 
and south. The total population of the district is approximately 1.8 million with a growth rate 
of 1.53 %. The district consists of 6 upazilas, 61 unions, and 361 villages. Upazilas are 
administrative and geographical sub-units of a district, which are also divided into unions 
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comprising approximately nine wards or villages. In Nilphamari, the six upazilas include 
Dimla, Domar, Jaldhaka, Kishoregonj, Sadar and Saidpur (Bangladesh Bureau of Statistics, 
2010).  
 
Figure 2.1 Nilphamari district and upazilas in the district. 
 
 
2.2.2 Clinical assessment  
The data recorded on patients found in the community included, their age and sex, location 
(upazila)  and a clinical assessment was conducted to determine the presence of a hydrocoele 
in males, lymphoedema of the limbs, breast and labial in females, and episodes of ADLAs, as 
per questionnaire. The standard form that the Bangladesh LF programme uses to collect data 
is shown in Figure 2.2. 
 
2.2.3 Data analysis and mapping 
All data were entered Microsoft Excel Version 12.3.6 (Microsoft Corp., Redmond, VA, USA) 
and analysed in IBM SPSS Statistics 22 IBM Corp., Armonk, NY, USA). Cross tabulation, chi 
square tests and independent samples t-test using a 5% significance level were used to 
determine the relationship between clinical disease and age, sex, and location.  
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Figure 2.2 Lymphoedema stages with translation into local language 
 
 
  
55 
 
2.3 Results  
2.3.1 Summary of number of cases and prevalence by upazila, union and gender 
 
In total there are 6 upazilas with 61 unions, 42 wards and 361 villages where clinical cases of 
LF were found (BBS-2011).  A summary of the number of cases by each upazila, union, sex 
and population of per 1000 are listed in Table 2.1. The overall number of cases of clinical LF 
was 11370 (Females-6773, males- 4596) and prevalence across the total population was 0.8% 
or 7.8 per 1000 people.  
The number of LF cases are highest in Jhaldkaka and lowest in Saidpur (Figure 2.3). 
Prevalence of LF cases were significantly higher in Jhaldhaka and lowest in Sadar. Jhaldhaka 
and Saidpur prevalence is significantly higher than other upazila showing in Figure 3.3. Total 
cases are significantly higher in Jhaldhaka Upazila in compared to other upazila. Male 
prevalence is even higher than females in this upazila as shown in Figure 2.3 A and B. 
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Figure 2.3 Summary data by upazila 
A. Total number of cases by gender and upazila  
                                    
 
B. Prevalence per 1000 people by Upazila   
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Table 2.1 Unions and number of clinical cases and infections in Nilphamari district 
 
Upazila  Union Male Female Total No. 
Total 
Population 
per 1000 
Dimla Bala Para 42 81 123 26863 4.58 
 Dimla 117 126 243 38403 6.33 
 Gayabari 86 113 199 18202 10.93 
 
Jhunagachh 
Chapani 81 52 133 
25146 5.29 
 Khalisa Chapani 62 106 168 24549 6.84 
 Khoga Kharibari 78 119 197 17916 11 
 Naotara 83 91 174 27564 6.31 
 
Paschim 
Chhatnai 25 66 91 
18303 4.97 
 Purba Chhatnai 12 39 51 12366 4.12 
 Tepa Kharibari 38 57 95 14663 6.48 
Dimla Total   624 850 1474 223975 6.68 
       
Domar Bamunia 61 99 160 13643 11.73 
 Bhogdabari 65 226 291 31513 9.23 
 Boragari 35 44 79 24794 3.19 
 Domar 94 59 153 33142 4.62 
 Gomnati 78 39 117 21419 5.46 
 Harinchara 64 54 118 14457 8.16 
 Jorabari 58 72 130 19842 6.55 
 Ketkibari 51 62 113 15058 7.5 
 Panga Matukpur 92 81 173 18938 9.14 
 Sonaroy 71 71 142 22893 6.2 
Domar Total   669 807 1476 215699 7.17 
 
Jaldhaka Balagram 202 366 568 23229 24.45 
 Daoabari 39 64 103 10025 10.27 
 Dharmapal 125 164 289 19729 14.65 
 Golmunda 85 105 190 21631 8.78 
 Golna 72 240 312 22029 14.16 
 Jaldhaka 142 335 477 31669 15.06 
 Kaimari 179 558 737 34824 21.16 
 Kanthali 118 366 484 19223 25.18 
 Khutamara 83 74 157 28776 5.46 
 Mirganj 95 211 306 22614 13.53 
 Saulmari 166 326 492 20245 24.3 
 Shimulbari 86 167 253 20742 12.2 
Jaldhaka Total              1392 2976 4368 274736 15.77 
Kishoreganj Bahagili 60 48 108 23290 4.64 
 Barabhita 63 45 108 22889 4.72 
 Chandkhana 85 117 202 26142 7.73 
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 Garagram 106 84 190 28012 6.78 
 Kishoreganj 55 39 94 35167 2.67 
 Magura 72 95 167 35360 4.72 
 Nitai 95 93 188 25333 7.42 
 Putimari 62 101 163 31098 5.24 
 Ranachandi 107 79 186 25901 7.18 
Kishoreganj Total 705 701 1406 253192 5.68 
 
Sadar Chaora Bargachha 45 74 119 21688 5.49 
 Chapra Saramjani 51 40 91 22905 3.97 
 Charaikhola 96 54 150 27300 5.49 
 Gorgram 43 53 96 24011 4 
 Itakhola 106 67 173 23231 7.45 
 Kachukata 137 152 289 21915 13.19 
 Khokshabari 12 49 61 20885 2.92 
 Kunda Pukur 58 95 153 27224 5.62 
 Lakshmi Chap 50 65 115 16351 7.03 
 Palasbari 39 5 44 18090 2.43 
 Panch Pukur 38 31 69 19712 3.5 
 Paurashava 65 53 118 40084 2.94 
 Ramnagar 70 58 128 20483 6.25 
 Sangalshi 30 21 51 18219 2.8 
 Sonaroy 40 62 102 25392 4.02 
 Tupamari 19 40 59 24389 2.42 
 Sadar Total   893 917 1810 371879 4.97 
       
Saidpur Bangalipur 27 43 70 16791 4.17 
 Bothlagari 61 92 153 30537 5.01 
 Kamar Pukur 59 136 195 22406 8.7 
 Khata Madhupur 38 49 87 19427 4.48 
 
Kushiram 
Belpukur 47 92 139 25855 5.38 
 Paurosova 74 109 183 4584 39.92 
Saidpur Total   306 521 827 119600 11.28 
 
 
Grand total       4596 6774 11370 1459081 7.79 
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2.3.2 Maps of the number of cases and prevalence by upazila and union   
 
The locations, number and prevalence of the upazilas and unions are mapped in Figure 2.4. 
the map A of upazilas shows higher number of cases are in Jhaldhaka upazila which is similar 
to the prevalence of map B which shows prevalence per 1000 population. Highest prevalence 
is in Saidpur Upazila paurosova is 39.92, seems very unusual, may be related to high density 
of population in Paurosova area. Union wise prevalence shows Kanthali (25.18), Saulmari 
(24.3), Balagram (24.45), Dharmapal (14.65) have higher prevalence per 1000 population. 
 
Figure 2.4 Maps of overall clinical cases and prevalence per 1000 people by union  
 
1. Case numbers                                                 B. Prevalence per 1000 
       
 
 
2.3.3 Summary of clinical conditions 
Lymphoedema of the leg and hydrocele were the most common condition with 5453 
individuals affected by lymphoedema and 5359 affected by hydrocele.  Only a small 
percentage (n=641; 5.6%) of these individuals had both legs affected. The next most common 
condition was found to be lymphoedema of the breast (n=320; 2.8%).  In total 105 men had 
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a combination of leg lymphoedema and hydrocoele (0.9 %).  There were differences between 
males and females and the conditions they were affected by, with females accounting for 
around three quarters of leg and arm lymphoedema and the most of breast lymphoedema 
as shown in Table 2.2. There are 148 women reported hydrocele, which could be female 
genitalia or miscoding, but not included in analysis. 
 
Table 2.2 The parts of the body affected by clinical conditions stratified by sex. 
 
Area of body affected Number of cases and percentage of total pre-condition 
Males (%) Females (%)   Overall  
Leg lymphoedema  1402 25.7 4051 75.3 5453  
Hydrocele 5359 100 ….  5359  
Arm lymphoedema 59 29.6 140 70.6 199  
Breast lymphoedema 22 6.9 298 93.1 320  
Leg lymphoedema/hydrocele 105 100   105  
       
 
2.3.4 Maps of clinical case numbers and prevalence by the specific clinical condition 
The geographical distribution of leg, arm, breast lymphoedema and hydrocoele cases is 
shown in Figure 2.5A-D. In total, every condition was reported in about half of the 62 unions 
(51.6%). High concentration of hydrocele cases were found in hotspot area (dark red) in 
Jaldhaka and part of Saidpur upazila Figure 2.5 A.  This differs to the lymphoedema, which 
are more spread out and higher proportion of diseases were found in more upazilas including 
Jaldhaka, Kishorgonj, Nilphamary Sadar and Dimla. For the other conditions, the arm 
lymphoedema, even though in lower proportion has almost similar distribution of leg 
lymphoedema. Distribution of breast lymphoedema is in focused area of Jaldhaka district. 
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Figure 2.5 Village location of LF patients  with clinical diseases 
A. Hydroceole (males only)                              B. Leg lymphoedema 
 
 
 
 
 
 
 
 
 
 
C. Arm lymphoedema                                                D. Breast lymphoedema 
 
 
 
 
 
 
3.5 Summary of clinical conditions by age 
 
 
 Increasing depth of colour-increase 
concentration of cases 
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Overall, the average age group of the individuals with lymphoedema is 40-49 years (%) was 
significantly higher than other age group. The number of cases and age-specific prevalence 
of LF disease increased with age (Table 2.3) (Figure 2.6). This increasing trend was also 
evident for leg lymphoedema and hydrocoele cases when examined separately as shown in 
table 3.3 and for age-specific prevalence as shown in figures 2.6 A and B.  Overall average 
age was 40 years. Average age is highest in Dimla (44.5 years) and lowest in Jhaldhaka (37.6 
years). Lymphoedema cases are more prevalent in females in increasing age. On the other 
hand, hydrocele is more common in 30-49 years age groups which is most productive period 
of life (Figure 2.6 B). 
 
Table 2.3 Age and sex distribution of lymphoedema cases 
 
Age group 
(years) 
Number of cases 
Male (%) Female (%) Overall  
10-19 129 46.6 148 53,4 277  
20-29 103 20.1 310 79.9 513  
30-39 210 19,3 879 80.7 1089  
40-49 369 23.4 1208 76.6 1577  
50-59 298 28.0 767 72.0 1065  
>60 290 31.4 634 68.6 924  
Total  1402  4051  5453  
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Figure 2.6 Lymphoedema and hydrocele case by age group. 
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2.3.5 Severity of leg lymphoedema 
 
A total of 2915 individual (Male-24.2% Female-75.8%) were found to have mild 
lymphoedema of the legs, 1718 individuals (Male-25.3%, Female-74.6%) had moderate and 
820 individuals (Male-31.7%, Female-68.2%) had severe stage (Figure 2.7). For the individuals 
with bilateral lymphoedema, the highest severity was recorded and included in the analysis.  
As shown in figure 2.7 about a half of population had mild stage (53.5%), about one third had 
moderate (31.5%) and 15% of total had severe stage of diseases. 
 
 Similar descending trend of severity of diseases were found in both male and females. A 
total of mild cases was higher than severe cases by 2095 in number.  Number of female cases 
were higher than male in all three groups. Females had significantly higher rates of disease 
in mild and moderate group but not in severe group than males as demonstrated in figure 
2.7.  
 
Figure 2.7 Number of leg lymphoedema cases by severity and gender 
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2.3.6 Acute Dermatolymphangioadenitis attacks (ADLA)  
The frequency of ADLA increased with severity of Lymphoedema on all groups. As shown in 
figure 2.8 and figure 2.9. in female’s frequency of ADLA with mild lymphoedema had -39.97%, 
moderate had 44.53% and severe had 45.61%. While male with lymphoedema had ADLA 
frequency 52.35% in mild, 59.02% in moderate and 64.39 % in severe. Male had a higher 
proportion of ADLA frequency.  About half of male (52.53%) and female (39.97%) with 
lymphoedema had ADLA in mild cases. However, severe cases had higher proportion of ADLA 
both in male (64.95%) and female (45.61%). 
Figure 2.8 Proportion of ADLA by severity of diseases-female 
  
Figure 2.9 Proportion of ADLA by severity of diseases-male 
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2.4 Discussion 
Overall prevalence in Nilphamari district is high which has been shown in other study (Aslam 
et al 1971). Prevalence is variable across the district, high in Jhaldhaka upazila, might be 
related to demography of Jhaldhaka, mosquito, for example, it could be related to poverty 
and availability of mosquito breeding sites. Like many other endemic area, hydrocele and 
lymphoedema were found to be the most common disability (WHO, 2013). Females were 
more commonly affected by lymphoedema and males were commonly affected by 
hydroceles, which is same as demonstrated by this research project (Hafiz I et al, 2015). 
This data shows about 80% of affected population had mild and moderate disease. Therefore, 
most of the people affected will mainly need home-based management (WHO-MMDP, 
2013). Remaining 15% of them are severe stage, who will require more intensive or 
specialised care. This severe group also has higher chance of ADLA. They need special 
treatment and referral for wound care. The National LF programme will need to establish a 
sustainable system of management for this group (Addiss et al, 2010 ). 
MMDP needs to consider the gender differences for targeting the programme. High 
prevalence of hydrocele was found to be quite localized. Therefore, hospitals and surgical 
teams can be trained in the areas for hydrocele surgery. As lymphoedema was more 
widespread the programme will need a different strategy. Mainstreaming of services into 
existing health system would be a sustainable option considering the recent stage of 
programme. 
Several studies showed MDA has effect on clinical condition (Ramaiah et al, 2014). For male’s 
hydrocele incidence may be reduced due to hydrocele camp organised by the national 
programme and private hospital in Saidpur. For remaining hydrocele condition hydrocele 
surgery camp, training of local hospitals and surgeon for hot spot area and to ensure quality 
assurance would be appropriate (Addiss et al, 2010; Dickson, et al, 2017). After stopping MDA 
it is now prudent for National programme to focus on remaining morbidity. 
The disabilities are high spread in community which has physical, socioeconomic and mental 
health effect (Ramaiah et al, 2014). This study shows males and females are affected 
differently by their lymphoedema. Age group mostly affected was found to be in midlife, who 
are the productive and active part of their life. These chronic conditions have negative impact 
on family wealth. It is also important to consider care giver and potentially they stop work to 
look after family members. 
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2.5 Conclusion 
Overall the baseline study found a heavy burden of disease in one of the most endemic 
districts in the northern part of the country. This provided key information to the LF 
programme and may have helped to plan the current morbidity management activities. It 
also helped to understand the proposition of diseases i.e how many hydrocele or 
lymphoedema to hand or breast – as well as information on the severity of disease. Hydrocele 
was the significant burden with men affected, mainly in their most productive years of their 
lives, which has economic implications for them and their families. However, the advantage 
for men with hydrocele is that it can be corrected with surgery. In contrast, women were 
more affected by lymphoedema which has important implication in the long-term as they 
will be affected by these conditions for decades. This information also indicates where the 
programme should target the most social mobilisation to ensure that everyone take MDA 
and receives treatment. 
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Chapter Three 
Cluster survey of lymphatic filariasis prevalence in Nilphamari 
District after a decade of mass drug adminsitration 
 
(Content of this chapter has been published in Trans. R. Soc. Trop. Med. Hyg. ;109 in 2015) 
3.1 Introduction 
In Bangladesh, the highest LF endemicity occurs in the northern region of the country where 
during the 1970-80s, and at the start of the LF programme, estimates of Mf prevalence were 
up to 17% with disease burden 10% (Wolfe et al. 1972; Barry et al. 1971). Nilphamari District 
is considered to have the highest levels of endemicity. A house to house clinical case 
identification survey conducted in 2005 by the Japanese International Cooperation (JICA) 
volunteers in collaboration with the LF programme (unpublished data), estimated the 
prevalence of clinical cases to range from 5 to 30 cases per 1000 population by union, which is 
the smallest local government administrative unit and presented in figure 3.1.  
Over the past 15 years, the LF programme in Bangladesh has concentrated its efforts on 
interrupting transmission through annual MDA with the two drugs albendazole and DEC 
(Ministry of Health and Family Welfare, Government of Bangladesh, 2010) These 
programmatic efforts have been very successful as measured by the TAS, following the 
guidelines by the WHO (WHO 2011a). Many districts are now considered to have interrupted 
LF transmission with few or no positive infections found among school aged children aged 6 to 
7 years old. However, a large number of cases with chronic clinical manifestations remain (WHO 
2011a; Hafiz et al. 2015). The National LF Elimination Programme has recently started to scale 
up activities related to morbidity. 
 
3.2. Methods 
3.2.1 Survey area  
Survey area is Nilphamari district as described in Chapter two. The district has 6 Upazilas, 61 
unions and 361 villages.The district consists of 6 upazilas, 61 unions, and 361 villages. 
Upazilas are administrative and geographical sub-units of a district, which are also divided 
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into unions comprising approximately nine wards or villages. In Nilphamari, the six upazilas 
include Dimla, Domar, Jaldhaka, Kishoregonj, Sadar and Saidpur (Bangladesh Bureau of 
Statistics, 2010). Since the beginning of the LF programme, the district has been prioritised 
for elimination and received 12 rounds of MDA, once in a year between 2002 and 2013 with 
coverage levels exceeding the standard WHO requirements of more than 65% of the total 
population. Recently transmission has been assessed and now considered to be interrupted 
as measured by TAS, with no positive infections found among the surveyed school aged 
children. 
 
3.2.2 Survey design  
 
To estimate the number of clinical cases in Nilphamari district, a two stage 30-cluster survey 
was conducted over a 4-week period in March and April 2011. The district had an expected 
clinical case prevalence of 5 to 30% based on the previous clinical case survey noted above. 
The proposed sample size of 1200 individuals was designed to estimate the true LF 
prevalence with a precision (i.e. 95% confidence interval) of ±1.2% - 2.6%; adding a design 
effect of 2 to adjust for likely clustering effects, the precision will be ±1.6% - 3.7%. It was 
estimated that an average of 4 to 5 eligible individuals lived in each household, which 
resulted in a sample size of approximately 300 households with between 1200 and 1500 
individuals being assessed for presence and severity of LF disease. 
 
Survey clusters were randomly selected from the list of all villages in the district available 
from the Bangladesh Bureau of Statistics (2010). A village was considered a cluster, and the 
location of each village was geo-referenced using a GPS. For each village, 10 households were 
randomly selected from the central point of the village. First, a random direction was selected 
by spinning a stick or bottle, and then every alternate household was selected. Empty 
households were replaced with the next household. This process was conducted until the 
geographical end of the village was reached, and then the team returned to the centre and 
repeated the random direction selection until 10 households had completed the survey. All 
household members over the age of 10 were asked to participate after explaining and 
reading an informed consent. An assent form was provided for children more than 10 years 
age.  
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3.2.3 Field team 
The data collectors consisted of experienced field workers who had worked previously with 
the LF programme on MDA implementation and survey activities. The lead investigator was 
a medical practitioner, who was working with the LF programme at the time of the survey 
and had extensive experience with LF patients, and therefore assessed all the clinical cases 
found during the survey. The team comprised the lead investigator, a final-year medical 
student, two experienced LF programme staff, and two field assistants who worked 
simultaneously in two groups in each village cluster. The field team was specifically trained 
before the survey to identify LF clinical cases, and if there was any confusion or ambiguity 
during the survey, the lead investigator reassessed the case to help reduce the chance of any 
cases being missed. 
 
Figure 3.1 Study site and number of patients per 1000 population 
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3.2.4 Clinical assessment  
For each individual included in the survey, their age and gender was recorded and a clinical 
assessment conducted to determine the presence of a hydrocoele in males, lymphoedema of 
the limbs, breast and labial in females, and episodes of acute dermatolymphangioadenitis 
attacks (ADLA).  
1. The severity of the hydrocoele was graded according to size measured in centimetres 
(cm): Grade I = size <15 cm diameter, Grade II = size > 15cm diameter.  
2. The severity of lymphoedema (legs only) was based on the Dreyer staging method 
(Dreyer et al. 2000) which included seven stages related to key clinical features as 
demonstrated in Dreyer et al, 2000 (Appendix iii)): 
 
➢ Stage 1: Swelling is reversible overnight; Stage 2: Swelling is not reversible 
overnight; Stage 3: Presence of shallow skin folds (base of the fold can be seen 
with movement of the leg); Stage 4: Presence of skin knobs; Stage 5: Presence 
of deep skin folds (base of the fold can only be seen if opened up); Stage 6: 
Presence of mossy lesions, warty looking epidermal skin lesions; Stage 7: Unable 
to care for self or perform daily activities (as tabulated in Smith et al).   
➢ Additional questions were asked related to the presence of entry lesions, 
interdigital lesions (including skin scaling, peeling, cracking, maceration, odour, 
pain, itching), lesion colour and dystrophic nails. 
3. The questions related to ADLAs included whether they were currently having an 
acute attack; the number of attacks experienced in the past 6 months, and the 
number of days each attack usually lasts. The 6-month average ADLA rate per person 
for men and women was quantified based on the total number of attacks reported, 
divided by the total number of individuals with lymphoedema and multiplied by 
1000. 
 
4. Clinical assessments were conducted in privacy as per individual’s request. 
Individuals found to have clinical conditions were provided with a hygiene kit and 
information on the management and treatment of their specific condition and 
referred to the local clinic.  
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3.2.5 Serological Infection rates 
A secondary objective was to establish the evidence of serological infection among the 
surveyed individuals. All individuals identified with LF clinical condition, and one additional 
individual per household to establish non-clinical infection rates, were invited to be tested 
for circulating filarial antigen (CFA) using the rapid diagnostic ICT card with 100ul of blood, 
according to manufacturers’ instructions (Weil et al , 2007).  Individuals who were found to 
be ICT positive were invited to be tested for Mf of W. bancrofti in night blood samples (60 ul 
blood on slides) collected between 22.00 and 23.00 h (McMohan et al, 1979). All positive 
individuals were offered standard drug treatment of albendazole and DEC, and information 
on preventive measures.  
 
3.2.6 Data analyses and mapping 
All data were entered into Microsoft Excel Version 12.3.6 (Microsoft Corp., Redmond, VA, 
USA) and analysed in IBM SPSS Statistics 22 IBM Corp., Armonk, NY, USA). Cross tabulation, 
chi square tests and independent samples t-test using a 5% significance level were used to 
determine the relationship between clinical disease and age, sex, and location. The location 
of the 30 village clusters and location of clinical cases were mapped using ArcGIS 10 (ESRI, 
Redland, CA). 
 
3.2.7 Ethical consideration 
               All the information provided by participants as a part of the study was kept confidential by 
research group. Data entry was anonymous and only a code number was provided during data 
entry. Papers and electronic copies of data are stored in a secure storage or password protected 
location where only the PhD student and supervisors have access. Any data in connection with 
the study will be used in a manner that does not disclose the identity of the subjects.  
Written consent to conduct the survey and blood collection as part of the serological survey was 
obtained. All the procedure were verbally discussed with the survey participants and additional 
permission to take photos was obtained. Before conducting the survey, a meeting with the local 
village/community leaders and local health officials was conducted. 
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3.3 Results  
3.3.1 Survey villages  
The selected 30 village clusters by each upazila and union of Nilphamari District are listed in 
Table 3.1. The locations of the village clusters are mapped in Figure 3.3 in relation to previous 
union level case data per 1000 population collected by JICA and the LF Programme in 2005 
(unpublished data). Each upazila had between three and nine villages selected, and four 
unions had more than one village selected which resulted in a total 30 villages across six 
upazilas and 23 unions of the district.  
A total of 1242 individuals from 297 households were surveyed, including 625 males (50.4%) 
and 616 females (49.6%). The distribution of males and females across the villages and 
upazilas did not differ significantly. The overall average age was 32 years, ranging from 10 to 
110 years (males 33 years, females 30 years).  
Figure 3.2 Photograph showing an assessment of the lymphoedema  
 
 
3.3.2 Clinical cases  
In total, 55 clinical cases were identified and are listed by village and union in Table 3.1.  The 
overall clinical LF prevalence was 4.4% (95% CI 3.4 to 5.7%) among those surveyed in this 
district (Table 3.2). Lymphoedema of the leg was the single most common condition with 25 
individuals (25/55; 45.5%) affected with this condition alone. Around one third of these 
individuals (8/25; 32.0%) had both legs affected. The second single most common clinical 
condition was hydrocoele with 22 individuals (40.0%) affected. Four individuals were found 
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to have lymphoedema of the breast (7.3%). Three had a combination of leg lymphoedema 
and hydrocoele (5.5%), one individual had a combination of leg and arm lymphoedema, and 
a hydrocoele (1.8%). Taking the clinical cases with combined pathology into account, a total 
of 29 individuals had leg lymphoedema and 26 individuals had hydrocoele. 
Table 3.1 Village clusters and number of clinical cases and infections in Nilphamari district 
No 
 
Upazila 
(No. surveyed; ICT 
tested) 
 
Union Village Lymph 
(leg) 
Hydro ICT MF 
1 Dimla   
(N=125; ICT=28) 
Dimla Uttar Tita para 1    
2 Naotara Akashkuir  1   
3 Tepa kharibari 
 
Char kharibari     
4 Domar  
(N=87; ICT=35) 
Bamunia Bamunia 1 2   
5 Domar  Chikonmati 3    
6 Jorabari 
 
Uttar Ketakibari     
7 Jaldhaka (N=294; 
ICT=77) 
Balagram Salangram 1 1 1 1 
8 Dharmapal Kherkati     
9 Golmunda union Tilai 1    
10 Golna Kharija Golna     
11 Mirganj Arazi Pathan para 2 2   
12 Shimulbari Banshdaha  2   
13 Saulmari 
 
Taluk Saulmari 1 1 2 1 
14 Kishoregonj 
(N=82; ICT=20) 
 
Kishoregonj Kishoregonj  1 1 1 
15 Kishoregonj Dakshin Rajib 3 1   
16 Sadar  
(N=353; ICT=122) 
Charaikhola Charaikhola  2 1  
17 Gargram  Gargram 4 4   
18 Kunda pukur Khoka para     
19 Kunda pukur Sutipara     
20 Sangalshi Kadikul  1   
21 Sangalshi musrat kukhapara 1    
22 Sonaroy Paschim Arazi Charaikhola  1   
23 Tupamari Dolua Dogachi 3 (+1)* 1   
24 Tupamari 
 
Sukhdhan     
25 Saidpur  
(N=301; ICT=65) 
Paurashava-ward 4 Atiar colony 1    
26 Paurashava-ward 7 Puratan babupara   1 1 
27 Paurashava-ward 12 Sahebpara Dakshin 2 1   
28 Paurashava-ward 15 Banshbari Uttar     
29 Bangalipur Lakshampur Charak Para  1   
30 Bothlagari union Kismat Kadikul 1(+4)** 4   
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*(+1) = arm lymphoedema 
** (+4) = Breast lymphoedema 
Upazila total population in 2011 (Census): Dimla 175,507; Domar 187,696; Jaldhaka 233,885 
Kishoregonj 199,422 Sadar 306,051 Saidpur 246,201 
 
The geographical distribution of the study sites recording any lymphoedema and hydrocoele 
cases is shown in Figure 3.3. There was no obvious geographical pattern to the distribution 
of either condition across the district. In total, at least one condition was found in 21 out of 
the 30 village clusters (70%), with 10 villages reporting both lymphoedema and hydrocoele, 
one village reporting breast and arm lymphoedema. The majority of households (n=30; 
76.9%) had one case only, while around a quarter of households had multiple cases. Three 
households (7.7%) reported two cases, 5 households (12.8%) reported three cases and 1 
household (2.6%) reported four cases (Figure 3.4).  The 55 cases were found in 39 out of the 
total 297 households. 
 
 
Table 3.2 Parts of the body affected by clinical conditions by gender 
 
Area affected Number of cases 
Males (%) Females (%)   Overall (%) 
Leg lymphoedema  6 (18.8) 19 (82.6) 25 (45.5) 
Hydrocele 22 (68.8) 0 (0) 22 (40.0) 
Breast 0 (0) 4 (17.4) 4 (7.3) 
Leg lymphoedema/hydrocele 3 (9.3) 0 (0) 3 (5.4) 
Leg lymphoedema/hydrocele/arm 1 (3.1)  0 (0) 1 (1.8) 
Total (Overall prevalence) 32 (5.1%) 23 (3.7%) 55  
 
Chi square test: p value= 0.000 
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Figure  3.3 Village location of LF patients  with clinical diseases and infection 
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Figure 3.4 Proportion of households with multiple lymphatic filariasis clinical cases. 
 
 
 
 
The overall LF disease prevalence was higher in males (5.1% (n=32)) than females (3.7% 
(n=23)) but the difference was not statistically significant (Chi sq = 1.4075,  p = 0.235). There 
were differences in the body parts affected as shown in Table 3.2. Males were predominately 
affected by hydrocoele, either alone or in combination with other conditions (hydrocoele 
total n=26; prevalence 4.2%). Two thirds of hydrocoeles were classified as Grade 1 (average 
age 42), and one third as Grade 2 (average age 51 years). Females were predominately 
affected by leg lymphoedema (n=19; prevalence 3.1%) representing two thirds of the total 
number (leg lymphoedema total =29) with double the lymphoedema prevalence of men. 
Overall, 13 (44.8%) lymphoedema cases had only their right leg affected, 8 (27.6%) had only 
their left leg affected, and 8 (27.6%) individuals had both legs affected. 
 
Overall, the average age of the 55 individuals with clinical conditions (47 years) was 
significantly higher than those without (31 years) (p<0.001). The number of cases and age-
specific prevalence of LF disease increased with age (Table 3.3) (Figure 3.4). This increasing 
trend was also evident for leg lymphoedema and hydrocoele cases when examined 
separately as shown in Table 3a and b. 
  
1 case 2 cases 3 cases 4 cases
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Table 3.3a Age and sex distribution of lymphoedema cases 
 
Age group 
(years) 
Number of cases 
Male (%) Female (%) Overall % 
10-19 0 0 0 0 0 0 
20-29 2 (20.0) 1 (5.3) 3 (10.3) 
30-39 0 (0) 2 (10.5) 2 (6.9) 
40-49 1 (10.0) 5 (26.3) 6 (20.7) 
50-59 5 (50.0) 5 (26.3) 10 (34.5) 
>60 2 (20.0) 6 (31.6) 8 (27.6) 
Total  10  19  29  
 
Chi square test: p value= 0.000 
 
 
Table 3.3b Age distribution of hydrocele cases 
 
Age group 
(years) 
Number of cases 
     Male                (%) 
10-19 2 (7.7) 
20-29 1 (3.8) 
30-39 8 (30.8) 
40-49 2 (7.7) 
50-59 5 (19.2) 
>60 8 (30.8) 
Total  26  
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3.3.3 Stage of leg lymphoedema 
A total of eight individuals (8/29; 27.6%) were found to have Stage 1 (3 males; 5 females), 
three individuals (10.3%) were at Stage 2 (3 females), 16 individuals (55.2%) were at Stage 3 
(5 males; 11 females) and only one male individual had bilateral lymphoedema with Stage 4 
and Stage 6 (3.4%) (Figure 3.3). None of the individuals surveyed had the most advanced 
Stage 7. For the individuals with more than one leg affected, only the highest Dreyer stage 
was included in the analysis. Similar average staging level was found between men and 
women, but there was a significant difference by age group (p<0.001). Additional questions 
relating to other skin conditions found only one female individual (Stage 2 lymphoedema) 
with entry lesions, interdigital lesions, skin peeling, skin cracking and pain. 
 
Figure 3.5 Acute dermatolymphangioadenitis attacks (ADLA) 
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At the time of the survey, four individuals (13.8%; 1 male, 3 females), reported suffering from 
an ADLA (Table 3.5). There was no significant difference in ADLA frequency by lymphoedema 
stage, gender or age group. The 6-month average ADLA rates were similar for men with 170 
ADLAs per 1000 lymphoedema cases (total 17 ADLAs/10 individuals) and women at 200 
ADLAs per 1000 lymphoedema cases (total 38 ADLAs/19 individuals).  When asked about the 
duration of attacks, three individuals (10.3%) reported they lasted 1 to 2 days, 13 individuals 
(44.8%) reported they lasted 3-4 days, five individuals (17.2%) reported they lasted 5 days or 
more (Table 3.5). There was no significant difference in ADLA duration by lymphoedema 
stage, sex or age group. 
 
Table 3.4 Frequency of acute dermatolymphangioadenitis (ADLAs) in the past 6 months in 
participants with leg lymphoedema by gender. 
 
Number of ADLAs in 
the past 6 months 
Number of participants 
Male (%) Female (%) Overall (%) 
None 4 (40.0) 4 (21.1) 8 (24.1) 
1 0 (00.0) 4 (21.1) 6 (20.7) 
2 4 (40.0) 6 (31.5) 9 (31.0) 
3 1 (10.0) 1 (5.3) 2 (6.9) 
4 0 (0) 2 (10.5) 2 (6.9) 
>5 1 (10.0) 2 (10.5) 3 (10.3) 
Total 10  19  29  
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Table 3.5 Duration of acute dermatolymphangioadenitis (ADLAs) in days in the past 6 
months in participants with leg lymphoedema by gender 
 
Duration of ADLAs in 
days in the past 6 
months 
Number of participants 
Male (%) Female (%) Overall (%) 
None 4 (40.0) 4 (21.1) 8 (27.6) 
1 to 2 1 (10.0) 2 (10.5) 3 (10.3) 
3 to 4 5 (50.0) 8 (42.1) 13 (44.8) 
≥ 5 0 (0) 5 (26.3) 5 (17.2) 
Total                                      10    19  29  
 
 
3.3.4 Evidence of Infection  
In total 353 individuals were tested with ICTs (39/55 clinical cases; 206/297 individuals per 
household; and 108/206 additional requests to be tested from individuals) as summarised in 
Table 3.6. Of the 39 individuals with LF clinical conditions tested, only one male with a 
hydrocoele (Stage 1) aged 56 years was ICT positive, and also found to be Mf positive. 
 From the 206 individuals without clinical conditions who were tested, three males were ICT 
positive (1.5%) aged 15, 35 and 50 years, with the latter two males also found to be Mf 
positive.  
From the additional 108 individuals requesting to be tested, two males were ICT positive 
(1.9%) aged 24 and 28, with the former male also found to be Mf positive. The number of 
individuals positive by ICT and Mf by village is shown in Table 3.1 and Figure 3.2. The 
difference between ICT positivity rates in clinical and non-clinical cases was not significant 
(p= 0.507, by Fisher’s exact test). 
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Table 3.6 Summary of individuals tested for infection  
Group Total 
No. 
No. 
tested 
by ICT 
No. ICT 
Positive 
% ICT 
Positive 
(95% CI) 
No. Mf 
Positive 
Clinical cases 55 39 1 2.6%  
(0.05 - 13.5%  
1 
Other main household 
members selected  
 
297  206 3 1.5% 
(0.3 - 4.2%) 
2 
Additional household 
members requesting 
testing 
108 108 2 1.9%  
(0.2 - 6.5%) 
1 
Total  353 6 1.7%  
(0.6 - 3.7%) 
4 
 
 
 
Figure 3.6 Photograph of conducting a rapid diagnostic test using the ICT card   
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3.4 Discussion 
The LF Programme in Bangladesh is making good progress towards elimination of LF with 
more than five rounds of MDA completed in all endemic districts. The majority of districts 
are now verifying the interruption of transmission through the standard WHO TAS. This 
cluster survey indicates an overall low prevalence of disease found in an historically endemic 
area of the country (Barry  et al, 1971). Further, very few individuals were found to have 
advanced stage disease and these people tended to be in the older age groups. 
It will be important to have systems in place to monitor the clinical cases and detect new 
cases that may develop over time from persons infected before the interruption of 
transmission. Health workers will be able to play a role in this as it has been shown that they 
can readily identify the stage of lymphoedema with high agreement, as well as refer patients 
for hydrocoele surgery (Dreyer et al, 2000). Integrating surveillance into the national health 
system will help to confirm the ongoing interruption of transmission and reduction in 
morbidity cases, and thus contribute to the successful elimination of LF as a public health 
problem (Ramaiah et al, 2014).  
The clinical cases were found to be wide-spread across the district with no obvious 
geographical pattern, which may be related to the relatively homogenous demographics of 
the population (BBS, 2015). It may also be related to the widespread poverty and ubiquitous 
nature of the local mosquito vector Culex spp. which thrives in poor domestic environments 
(Aslam khan et al, 1972, Ahmed  et al, 1986). However, it is important to further investigate 
and understand why no evidence of disease and infection were found in eight (around one 
quarter) of the villages across the district. It may be because these villages are somehow 
different to the others, or it could be that the cluster survey may not be the most suitable 
method for detecting LF cases at village level. 
Currently there is no specific survey method recommended for identifying and mapping 
clinical cases on a large geographical scale. However, there are new community-based tools 
using phone technology being developed and trialled in endemic areas of Africa, resulting in 
linked geo-referenced morbidity databases of village-level information that will help to direct 
resources (Stanton et al, 2014).  The use of such innovative tools to improve detailed 
morbidity mapping in Bangladesh and other LF Programmes is increasingly important as they 
move their efforts towards scaling up MMDP. Furthermore, the WHO will most likely require 
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clinical case estimates, as well as evidence of service access and delivery, before considering 
the verification of elimination (Addiss et al, 2007 and Brady et al, 2014).   
Overall males and females had similar prevalence estimates but were affected by different 
conditions. Males were mostly affected by hydrocoele, and females by leg lymphoedema, 
which is a disease pattern that has recently been found elsewhere in a post-MDA setting 
(Smith et al, 2014 and Stanton et al, 2015). Public health campaigns and MMDP strategies 
will therefore need to take these gender differences into account to ensure the right 
messages and appropriate care are tailored to the right population sub-groups. Groups with 
milder or emerging evidence of disease may be more readily treatable and their condition 
potentially reversible with specific treatment strategies. However, there is as yet little 
information and no specific method for detecting the early stages of disease in endemic areas 
that would be practical to implement across a country such as Bangladesh as part of the 
National LF Elimination Programme (Gordon et al., 2011).  
The fact that few very advanced clinical cases were found in this survey suggests that the LF 
Programme could consider a predominantly home-based morbidity control protocol for 
lymphoedema cases. A recent review of research indicated that early use of simple hygiene 
measures, self-massage, limb elevation and exercise have the capacity to limit the severity 
of lymphoedema (Douglas et al, 2013, Mues  et al, 2014). However, for hydrocoeles, the vast 
majority of affected individuals will require surgery. The expansion of training and provision 
of resources to support district-level surgical teams is critically important to address the 
burden in men, especially as surgery significantly improves the quality of their Plives and 
ability to work (Stanton et al, 2015, Babu et al., 2009, Athorlu et al, 2001, Capuano et al, 
2012). It may also be possible to treat milder hydrocoele cases with non-surgical drug therapy 
such doxycycline. This practice is currently not a standard recommendation and may not be 
effective in all situations (Debrah et al, 2014) but it could be a highly beneficial and cost 
effective intervention for LF Programmes (Mand et al, 2012, Debrah et al, 2006, Mand et al 
2009, Hoerauf et al, 2011, Wanji et al, 2009, Taylor et al, 2010).  
Doxycycline has been identified as an anti-morbidity drug for the treatment of filariasis 
(elephantiasis) (Taylor MJ et al., 2005). On study shows minocycline is superior than 
doxycycline regimen as anti Wolbachia macrofilacide (Sharma R., et al, 2016). Mand, S., et 
al.,2012 has demonstrated Doxycycline improves filarial lymphedema independent of active 
filarial infection in a randomized controlled trial. 
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 The future study will focus on testing a defined panel of registered tetracyclines and novel 
tetracycline derivatives for improved anti-morbidity effects, focusing on in vitro and in 
vivo assays of anti-angiogenic / anti-inflammatory modes of action 
The clinical conditions of LF in general are known to have a detrimental impact on people’s 
lives (Stanton et al., 2015, Zeldenryk  et al, 2011, Zeldenryk  et al, 2013, Martindale et al, 
2014, Krishna Kumari  et al, 2005, Litt  et al, 2012), but, the incidence and specific effect of 
ADLAs is one aspect that is not well understood. The scope of the ADLA problem and 
contribution of attacks to an individual’s disability, poor socio-economic status and mental 
well-being is likely to be underestimated, as highlighted in a recent survey in Malawi 
(Martindale et al, 2014). As in Malawi, in Bangladesh the majority of lymphoedema cases 
experienced ADLAs regularly during a six-month period with an average episode lasting 
several days. We acknowledge that there may be recall bias in asking individuals to 
remember and report such attacks, but this does provide some key information to be 
investigated further. Understanding the physical impact and the role of ADLAs in the 
progression of the disease, as well as how they may influence the socio-economic status of 
individuals and their families, need to be priority areas of research to improve MMDP 
strategies. 
This was the first cluster survey to investigate the number of LF clinical cases and infections 
in Bangladesh after an extensive period of mass drug treatment. Other countries should 
consider a similar methodology to help develop and promote their MMDP strategies. We 
found some evidence of persistent infection in the district, with a small number of ICT and 
Mf positive individuals providing a possible reservoir of infectious individuals. While the low 
rate of ICT positivity in people with clinical filariasis is not a new finding, the extent to which 
this is a problem among family members warrants further investigation. Many people 
refused to be tested or were not at home during the survey, and no information on their 
migration history was undertaken. It is possible that future surveillance activities associated 
with the interruption of transmission could be linked with MMDP activities in the future, as 
both activities are key components of the LF Programme and their successful implementation 
is essential for the endgame (WHO, 2013, Ramaiah et al, 2014, WHO, 2011).  
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3.5 Conclusion 
This study conducted in an historically LF endemic district after more than a decade of MDA 
to interrupt transmission, highlights the overall low prevalence of advanced stages of disease 
and that the Bangladesh LF programme will need to develop the different MMDP strategies 
to address the diversity of needs related to the low prevalence of LF disease in younger age 
groups, the overall lack of advanced stage disease, the significant differences in conditions 
between males (hydroceles) and females (leg lymphoedema), and the potential detrimental 
impact of ADLAs.   
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Chapter Four 
Knowledge, attitude and practice (KAP) of community 
members and patients of lymphatic filariasis  
4.1 Introduction 
Understanding the community knowledge of disease and what they perspectives on control 
programmes is important. A KAP study conceptual framework has been traditionally used for 
behavioural changes in health sectors. KAP study meaning is explained in figure 4.1. There 
are many ways to extract information from patients.  However, the most common approach 
is a survey method known as Knowledge, Attitude and Practice (KAP). KAP studies on LF have 
been done in Indonesia (Krentel et al., 2006), Haiti (Mathiu et al, 2004) and Malaysia (Al Abd 
et al, 2014) which demonstrated very useful information about LF and its elimination 
programme. Furthermore, these studies helped to develop better message for public 
campaign. To date no study has been conducted in Bangladesh. 
The aim of this study therefore was first to conduct a survey on local community members 
to determine their KAP of LF, and second to specifically to elicit information from individuals 
affected by clinical condition of LF and ask them generally about their morbidity 
management. 
Figure 4.1 KAP Study meaning. 
 
KAP conceptual framework 
(Source;https://www.google.com.au/search?q=kap+study+conceptual+framework&source
=lnms&tbm=isch&sa=X&ved=0ahUKEwjdwvKK_LrZAhULxbwKHQg8BgQQ_AUICigB&biw=12
42&bih=557&dpr=1.1#imgrc=xhtZEbg4M6cVlM) 
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Figure 4.2 KAP Model 
 
Source: (Saugstad et al, 2003) 
4.2 Methods: 
4.2.1 Study site and sampling strategy 
The study was conducted in Nilphamari District in the same villages and households as those 
described in Chapterthree, which contains details of the study area and sampling 
methodology. Briefly, the household KAP survey was conducted as part of a cluster survey, 
where individual villages were considered clusters, which were randomly selected from the 
list of all villages in Nilphamari. For each village cluster, 10 households were randomly 
selected from a central point. Within each household, the head of the household over 18 
years of age was invited to participate in the survey, or if an individual with LF clinical 
conditions were present, then they were invited to participate as in the survey with the 
permission of the head of the household. Only one individual per household was included in 
the survey. 
 
4.2.2 Questionnaire  
For each individual included in the survey, socio-demographic information and questions on 
a range of topics including knowledge of filariasis, Knowledge of treatment and prevention 
Opinions on transmission and elimination and clinical management and impact were collected, 
collated and analysed. A summary of the five main sections of the survey and the related sub-
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sections (question themes) are summarised below. The full questionnaire in both English and 
Bengali are available in the Appendices.  
1. Socio-demographic characteristics  
➢ Upazilla 
➢ Sex 
➢ Age 
➢ Education level 
➢ Occupation 
➢ Religion 
 
2. Knowledge of filariasis  
➢ Knowledge of LF  
➢ Source of information 
➢ Symptoms of disease 
➢ Type of disease 
➢ Method of transmission 
 
3. Knowledge of treatment and prevention  
➢ Main method of prevention 
➢ Knowledge of MDA   
➢ Participation in MDA 
➢ Source of information of MDA 
➢ Mosquito control /personal protection 
 
4. Opinions on transmission and elimination (scale – agree/disagree statements)  
➢ Transmission– personal contact, a curse, same house living   
➢ Prevention/treatment – curable, vaccination, elimination possibility 
 
Section refers to patients only 
5. Clinical management and impact  
➢ Additional clinical conditions – pain, redness, odour, fever, heaviness  
➢ Difficulties on aspects of life – walking, household work, occupation, 
moving/travelling 
➢ Measures take to alleviate condition 
➢ Training and supplies to look after condition   
➢ Hydrocele specific – knowledge of treatment, surgery  
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4.2.3 Data analyses and mapping 
All data were entered into Microsoft Excel Version 12.3.6 (Microsoft Corp., Redmond, VA, 
USA) and analysed in IBM SPSS Statistics 22 IBM Corp., Armonk, NY, USA). Cross tabulation, 
chi square tests and independent samples t-test using a 5% significance level were used to 
determine the differences between variable and the relationship between KAP and age, 
gender. 
4.3 Results 
 
4.3.1 Socio-demographic characteristics  
A total of 297 people of 297 households had been participated in the study. 3 households 
refused to participate in the survey. Of the 297 respondents, 97 (32.7%) were male and 200 
(67.3%) were female.  The general socio-demographic characteristics of the respondents 
were presented in table 4.1. Overall the mean age of respondents was 36.47 + 15.02 years. 
The average age for males was 41 years and for females was 34.3 years. Most of participants 
are in age group of 21-30 (27.3 %) and 31-40 (23.3 %) years, while the age group > 70 years 
had least number of participants. Of the respondents 99.7% had received educated: 61.3% 
at the primary level, 25.9 % at the secondary level and 4.7% at tertiary level. About 56.6% of 
respondents were housewife, 12.1% were doing agriculture, 9.5% were businessman, 8.4 % 
were day labour and 8.1% were students. Of the total respondents 89.6% were Muslims, 10% 
were Hindu and 0.3% were Buddhist. 
 
4.3.2 Knowledge of filariasis  
When the respondents were asked about if they knew of LF, the vast majority (98.0% n=291) 
stated that they that heard about filariasis as shown in Table 4.2.  When asked about the 
source of information, the majority receive from the health worker (74.1%). 
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Table 4.1 Socio-demographic characteristics of study population. 
Variable Number (N=297) Percent (%) 
Sex   
 Male 97 32.7 
 Female 200 67.3 
Age   
  11-20 years 47 15.8 
  21 - 30 years 81 27.3 
  31 - 40 years 75 25.3 
  41 -50 years 47 15.8 
  51 - 60 years 24 8.1 
  61 - 70 years 19 6.4 
  71 - 80 years 4 1.3 
Educational level   
  Illiterates 1 0.3 
  Primary 182 61.3 
  Secondary 77 25.9 
  Higher secondary 23 7.7 
  Graduation 13 4.4 
  Post-graduation 1 .3 
Occupation   
  Agriculture 36 12.1 
  Service 8 2.7 
  Business 28 9.4 
  Day labour 25 8.4 
  Technical 1 .3 
  Housewife 168 56.6 
  Student 24 8.1 
  Others 7 2.4 
Religion   
  Muslim 266 89.6 
  Buddhism 1 0.3 
  Hinduism 
30 
10.1 
 
 (n=297): No people were there in 3/300 Houses. 
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70.7% knew about diseases from diseased friend while 44.1% knew from leaflet-folder 
supplied by Filariasis elimination programme. About 45.8% knew from television as 
demonstrated in the table 4.2. There was some variation found in the study between male 
and female. Female were getting information about disease primarily from Health Assistants, 
Doctors, folders/leaflet and friends while male respondents were getting information from 
radio and newspapers, miking, and doctors. 
 
 About 72.4% of respondents responded that they knew about symptoms of filariasis while 
27.6% responded negatively. About 77.2% responded that pain is main symptom of Filariasis 
and 64.7% knew about fever as a main symptom of Filariasis. Regarding main symptoms, 
about 85.1% and 96.3% knew urticaria and gradual swelling subsequently. Moreover, 
majority of them (90.2%) opposed to false statement about diarrhoea and vomiting, being a 
main symptom of Filariasis. Very few number of respondents mentioned about vague 
symptoms like cannot eat, cannot walk and vertigo shown in figure 4.3.  
 
Regarding type of disease, only about 10.4% told it is an infectious/contagious disease it. The 
rest of the respondents stated that filariasis is a hereditary (30.3%) or tumorous/cancerous 
(1.7%) condition, while 44.8% stated they did not know what type of disease it is, as shown 
in the Table 4.2. When asked about mode of transmission of disease, almost half (44.4%) of 
respondents stated filariasis is transmitted through mosquito bites. 6.1 % told that it is 
transmitted through food/water and 4.4% told about personal contact while 41.1% 
mentioned they don’t know the mode of transmission. Only 3 % stated it was spread through 
cough/sneezing (Table 4.2). 
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Table 4.2 Respondents’ knowledge of lymphatic filariasis 
 
Variable Number (N=297) Percent (%) 
Knowledge about lymphatic filariasis N=297  
  Yes 291 98 
  No 6 2 
Knowledge about symptoms of disease N=297  
  Pain 167 26.5 
  Fever 142 22.5 
  Urticaria 34 5.4 
  Vomiting & diarrhea 23 3.6 
  Gradual swelling of different parts of 
  Body 
265 42.0 
Source of information (Multiple response)   
  Health assistant 220 74.1 
  Doctor 52 17.5 
  Radio 23 7.7 
  TV 136 45.8 
  Newspaper 35 11.8 
  Diseased friend 210 70.7 
  Leaflet-folder 131 44.1 
  Miking 89 30.0 
Method of transmission N=297  
  Through food/ water 18 6.1 
  Personal contact 13 4.4 
  Mosquito bite 132 44.4 
  Sneezing /Cough 9 3.0 
  Other 3 1.0 
  Don't know 122 41.1 
Knowledge about what type of disease N=297  
  Infectious/contagious 31 10.4 
  Hereditary 90 30.3 
  Tumorous/cancerous 5 1.7 
  From bad air 11 3.7 
  Other 27 9.1 
  Don't know 133 44.8 
Knowledge about MDA as preventive measure  N=297  
  Yes 273 91.9 
  No 9 3.0 
  Don’t know 15 5.1 
   (n=297): No people were there in 3/300 houses. 
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4.3.3 Knowledge about treatment and prevention 
 
When asked about the main method of filariasis prevention, the majority stated that MDA 
from the national LF programme (92%), however a large percentage also mentioned the use 
of bed nets (64%) and household vector control (43.1%) with very few people stating other 
factors such as indoor residual spraying, vaccination or other as shown in Figure 4.4. 
 
Figure 4.3 Knowledge of preventative measure for filariasis 
 
When asked about MDA as a preventive measure, 91.9 % respondents that they have 
knowledge about MDA and 8.1% said they have no idea about MDA. Among the participants 
about 37.4% participated 5 times and more than half of respondents participated in 1-4 times 
in MDAs shown in table 4.3. Of the 6.4% respondent who did not take MDA, the main reasons 
were related to i) they did not receive the medicine (n=18; 6.1%), ii) they were absent from 
home (n=16; 5.4%), iii) lack of awareness (n=18; 6.1 %) and iv) Fear of side effect (n=12; 4%). 
Regarding source of information about MDA, 81.6% knew from health workers (related HW 
Chapter), 11.8% informed they are aware (Table 4.3) about MDA and rest of people are 
informed by doctors, Television/radio, loud speakers/miking and leaflet etc. Regarding 
prevention of disease, 65% informed that LF can be prevented by taking drugs in MDA once 
in a year for subsequent 5 years and 35 % said they don’t know. When asked from where 
programme free of cost. 
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When asked about preventive measures from mosquito bite, about 98% informed that they 
use any sort of protection measures. Among them majority of them use mosquito net 
(97.6%). A few respondents use mosquito coil, spray and electric coil. Most of the 
respondents (84.5%) also mentioned they clean their surrounding area for vector control.   
 
Table 4.3 Respondents’ knowledge of MDA 
 
Variable Number (N=297) Percent (%) 
Knowledge about MDA as preventive measure  N=297  
  Yes 273 91.9 
  No 9 3.0 
  Don’t know 15 5.1 
Participation in MDA N=288  
  O times 20 6.4 
  1 times 30 10.1 
  2 times 46 15.5 
  3 times 63 21.2 
  4 times 18 6.1 
  5 times 111 37.4 
Media of knowing cause of taking medication 
in MDA  N=272  
  Advised by Health Assistant 222 81.6 
  Advised by doctors 7 2.6 
  Informed by Radio, TV 1 0.4 
  Aware about prevention of LF 32 11.8 
  Want to prevent transmission of LF 6 2.2 
  Want to protect future generation  0 0.0 
  Other 1 0.4 
  Don't know 3 1.1 
   (N=297): No people were there in 3/300 houses. 
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Figure 4.4 Additional signs and symptoms experienced by individuals with clinical 
conditions  
 
Figure 4.5 Difficulties experienced by individual with clinical manifestations 
 
 
4.3.4 Measures taken alleviate condition 
Questions related to morbidity to get relief, advise from doctors, length of use of measure, 
type of improvement noticed, whether it was easy to implement. Overall, they were found 
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to not practice the measures regularly as shown in Table 4.4 and Figure 4.7. However, some 
of them (13 out of 26) use cleaning/washing with soap and some of them (11 out of 26) are 
wearing sandals. Nobody uses bandages at all. Very few of them do exercise (5 of 26) and 
practice leg elevation (4 of26). Furthermore 5 of 26 use traditional method. 
4.3.5 Training and supplies  
On total only 4 people (male-1 & female-3) stated that they have received training for their 
clinical condition. When asked about supplies provided from the government only one 
person stated they have received soap. 
4.3.6 Hydrocele patients 
When asking about treatment, all of hydrocele patients stated that they knew about surgical 
treatment. However, 3 out of 12 (25%) of them have already had surgery. Main reason for 
not having the operation was related to i) lack of awareness-25%, ii) it is expensive-50% and 
iii) fear of side effects 8.3%. None of the respondents stated that the reason was related to 
the lack of a facility in the local centre. 
 
Table 4.4 Morbidity control measures practiced presented as number 
 
Figure 4.6 Morbidity control measures practiced presented as proportion 
 
 
 
 
Measures practiced 
Never 
practiced 
 
Do regularly 
 
Do 
sometimes 
No response 
     
Leg elevation 15 1 3 7 
Exercise 15 1 4 7 
Wash with soap 12 4 4 6 
Sandel wearing 9 2 9 6 
Cleaning 7 4 9 6 
Bandage 20   6 
Use medicines 14 3 3 6 
Use traditional methods 15 3 2 6 
Other 20 0 0 6 
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4.4 Discussion 
Overall most people have heard of LF and three quarters could name specific symptoms 
correctly (positive). However, nearly half did not know the type of disease. About one third 
said it is hereditary disease. Only 10% identified it as an infectious disease. When asked about 
how it caused approximately half said it is transmitted by mosquito. This suggest that 
campaign focused on certain aspect of disease and may be the information needs to be 
expanded (Ramaiah et al, 2011). 
 
Source of information of LF in this study shows similar findings in study in Malaysia KAP study. 
High proportion of them received information from health workers and a diseased friend and 
someone from the community (Al Abd et al, 2014). In this study people were able to provide 
multiple responses. In highly endemic area, obviously people know from diseased friend. 
Interestingly there was difference between man and women and women mostly getting the 
information from health workers and male from newspaper, Radio, Television suggest that 
health massages need to be targeted to different subgroups. Considering the fact massage 
delivery needs to target the focus group. This may be important for man to encourage for 
hydrocele surgery with Radio and TV program. 
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A range of opinion was sorted on aspect of transmission and the possibility of elimination. 
Overall high proportion of the statement was positive and all correct. However, there was 
some clear misconception for example approximately a third of surveyed potentially thought 
that bad air, personal contact and living in the same house can be the cause of LF 
transmission. Also 20% thought of it is a curse. In contrast many people believed that LF 
elimination is possible which is a positive and may reflect the successful MDA and public 
health campaign driven by Bangladesh LF elimination programme which really highlights the 
elimination possibility.  Similar result was found in KAP study in Indonesia (Krentel et al, 
2006). 
The specific questions to patients with clinical condition highlighted that in addition to LF 
related condition they are suffered from pain, redness and heaviness (Ramaiah et al. 2013). 
Although majority has no formal training or no free supplies from Govt, most of them/all 
practiced cleaning using soap and water, which is an important recommendation from WHO 
MMDP (WHO_MMDP, 2013). The fact that no one reported bad odour and only one has 
fever.  This suggest that they were managing their condition with basic measures and there 
were very infrequent episodes of ADLA.  Recent reviews and studies showed that these 
measures are effective preventing ADLA (WHO-MMDP, 2013). However, this study is limited 
with few number of patients. Further studies can be done on these issues. 
 Obviously LF patients has difficulty in different aspect of life and we asked only few questions 
on it. They highlighted range of difficulties such as walking, working, travelling. However, 
Martindale highlighted that advanced stages are related to more difficulty in walking, 
travelling in compared to early stage of diseases (Zeldenryk et al, 2011, Zeldenryk et al, 2013, 
Martindale et al, 2014). However, more in depth study can be conducted about social and 
economic impact of LF and quality of life. 
Most of them are aware about mosquito control and also this study showed that they are 
aware about mosquito control (Ref- Malaysia study) and they clean the environment and use 
mosquito net which might have impact on LF and other mosquito borne diseases like malaria, 
supporting the integrated NTD model (WHO, 2013).  
Some misconceptions about the treatment – is that 18% thought that it could be cured by 
one dose of drug and nearly one third did not know the accurate MDA medicines – this has 
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implications for the national programme and these populations/ communities need to be 
targeted. 
The main treatment practiced in the affected community is washing, skin care, cleaning 
which is recommended in WHO MMDP programme, indicating that National LF programme 
has initiated to focus on morbidity management (WER, 2017). 
Different preventive measures are practiced in different areas. For example in some upazila 
had high MDA as well as bed nets and IRS and other have very low use of mosquito net, may 
be affected by other mosquito borne diseases program. 
 
Our study was the first KAP survey in South-east Asia to precede a health promotion 
campaign and MDA and thereafter. The results of round 1 are in line with results from studies 
in other areas with a different socio-demographic background. More people knew about the 
main symptoms of LF such as lymphoedema and hydrocele than about the disease name 
‘filariasis’ (Eberhard et al. 1996). Male individuals appear to be more aware of the symptoms, 
especially hydrocele than females (Babu et al. 2004). In most communities it is not widely 
known that mosquitoes transmit the disease agent and very fewer individuals know that 
worms in the blood cause the disease (Eberhard et al. 1996; Babu et al. 2004; Das et al. 2005). 
Some studies even do not strictly differentiate between vector and disease agent (Ramaiah 
et al. 1996; Das et al. 2005).  
 
We observed in our study population some interchangeability between transmission and 
cause of LF. A study from Haiti indicated that knowledge about the symptoms of LF, its 
transmission and control has a positive impact on the compliance of MDA (Mathieu et al. 
2004). This is supported by our results where 89% of the individuals who knew about filariasis 
and completed the questionnaire also reported participation in MDA. We have established 
that it is essential to provide the community with basic information about treatment and the 
possibility of adverse reactions; however, it is also important how the communication 
campaign is conducted. The KAP survey in round 1 and previous anthropological studies 
provided the research team with concrete information (Krentel et al., 2006). 
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4.5 Conclusion 
Overall good knowledge of the community – reflects a good LF programme. However, home 
based morbidity programme is not adequately well understood by the affected people. Even 
though there are less number of advanced cases, it is crucial to prevent deterioration of their 
disability by enforcing self-care. They need to be adequately trained for self-care or care by 
family members or community self-help group where applicable.  They need to be aware 
about referral/seeking help to main stream health services specially for surgery of hydrocele 
and ADLA management. However, they need to be educated about negative implication of 
traditional practices like cutting by knife or fish bone. Community self-help group and 
community leaders can play an important role in this aspect or alleviation of stigma related 
to long term disability from LF.  
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Chapter Five 
Workload, experiences and perspectives of community 
health workers  
  
5.1 Introduction  
The National LF Elimination Programme commenced in 2001 and has been very successful in 
the scale up of MDA, reducing prevalence to zero and is now well into the post-MDA 
surveillance phases (Shamsuzzaman AKM et al., 2017). Along with MDA, morbidity control 
activities have also been scaled-up gradually in recent years by the LF programme primarily 
through home-based care programmes. These have been run by community health workers 
(CHWs), who are also involved in all primary healthcare activities such as immunization 
campaigns, polio eradication, maternal and child health, malaria and kala-azar control as well 
as working on NTD programmes.  
The CHWs are the first point of contact for health-related issues in the community in 
Bangladesh. They are a non-professional group of people who have shorter training than 
professional health workers and can work both in community and health facilities on a paid, 
voluntary or part-time basis depending on the setting. The main source of paid income may 
include a salary from the government and/or incentives from non-government organisations 
(NGOs) for work on primary healthcare activities, and from development partners such as 
World Bank, USAID, UKAID which are directed through government programmes. The CHWs 
are trained and supervised by teams at sub-district (upazila) level including the Upazila Health 
and Family Planning Officer, Medical Officer of Disease Control, and the Upazila Health 
Inspectors, who have been trained by district health officers and the National LF Elimination 
Programme team.  MMDP training modules are developed from the standard WHO guideline 
and training materials (WHO 2017, WHO 2013).  
The CHWs play a key role in patient care and understanding their potential contributions as 
well as their challenges may be critical to the success of the MMDP component of the 
programme (Corley, et al., 2016).  The LF Programme included some training on MMDP 
activities at the same time as the MDA training programme; however, the knowledge and 
effectiveness of CHWs were not assessed (Hafiz et al., 2012).  It is also not known what the 
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ideal number of visits or how long each CHW should spend with patients as there are 
currently no recommendations. This study builds on the previous paper by Hafiz et al. ( Hafiz 
et al., 2015) in Nilphamari District, which identified LF morbidity (lymphoedema or 
hydrocoele) in 4.4% of persons over 10 years of age.  Since chronic and stigmatizing disability 
from LF occurs many years after infection, the highest burden of disease was observed in 
those over 50 years of age. The overall prevalence of LF morbidity did not differ between 
males and females, but the type of disease differed since only males can suffer from 
hydrocele.  There were more lymphoedema cases in women (Hafiz et al., 2015).  
The current paper provides insights into the workload, experiences and perspectives of male 
and female CHWs in a highly endemic region of Bangladesh before the scale up of MMDP 
activities by the National LF Programme in 2013. Although not one of our pre-specified 
analysis objectives, it became clear during the analysis that there were important differences 
between men and women in some responses. Therefore, we compared the CHW 
characteristics by gender as well as other characteristics.  The study provides information on 
the extent of male and female CHW’s work in terms of number of patients, frequency of 
visits, training, knowledge of disease, patient care and advice, and programmatic activities. 
The study was conducted in 2011 and provides an important baseline for LF programme in 
which to assess the experiences of CHWs over time as the MMDP component of the 
programme develops. 
 
5.2 Methods 
5.2.1 Study design  
A cross-sectional survey was conducted in Nilphamari District, a representative endemic 
district in the nrthern region of Bangladesh, to examine the male and female CHWs’ practice 
in the control of morbidity, their knowledge of LF disease and their opinion of programmatic 
activities. Based on the cluster survey areas described in (Hafiz et al., 2015) CHWs were 
randomly selected from a list within the same catchment area and asked to participate in the 
survey.  None of the CHWs approached refused to be interviewed. The total number of CHWs 
selected was 61 and thus the sample represents 28.8% of the total of 212 CHWs working in 
the district. Usually there is one community clinic for 6000 population, covered by one CHW. 
However, not all communities have their own CHW, and some of the CHWs work for double 
the population.  The district consists administratively of 6 upazilas, 61 unions and 361 villages.  
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To maintain confidentiality of the health worker respondent, the data were analysed at 
upazila level (the next administrative level below district) only. A semi-structured 
questionnaire was implemented with three main themes and a subset of specific questions. 
The questionnaire was done on paper by an interviewer.  The questionnaire was semi-
structured in that it contained a mixture of multiple choice, scaled and open-ended answers 
for which text responses were given.  The responses from the open questions concerning the 
CHWs’ work and experiences were presented in the paper as quotations.  The questionnaire 
was pretested in the local community prior to initiating the fieldwork.  
The first main theme was related to demographic and workload characteristics, and included 
questions on; 
- demographics (location, sex, age, education, income, religion, marital status) 
- work history (length of time in service, length of time in community)  
- training (received for morbidity management) 
- workload (number of patients in area, number of patients visited in last 6 months, number 
of times patients visited in last 6 months, length of time spent with patients per visit)    
 
The second theme was related to knowledge of disease, prevention and morbidity 
management, and included the following; 
- knowledge of disease (main signs and symptoms, type of disease, cause of disease, main 
methods of prevention) 
- knowledge of LF programme (time and frequency of MDA, name of drugs distributed) 
- patient identification and service (patient diagnosis, provision of patient care)  
- morbidity practice (health worker advice, additional measures conducted by patient, support 
provided by LF Programme)  
 
The third theme was related to opinions of training, morbidity management and 
programmatic activities, and included questions on  
- Training (duration, usefulness, adequate in content, length of time, practicality, suggestion 
for improvement) 
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- Morbidity management (allocated time with patients, main causes of insufficient time, 
effectiveness of programmatic measures, caring for patient with advanced disease, main 
problems and suggested solutions with provision of care) 
- Programmatic activities (elimination potential, participation in MDA programme, coverage 
rates, reasons for non-compliance)  
 
5.2.2 Data analysis 
All data were entered Microsoft Excel Version 12.3.6 (Microsoft corporation, USA) and 
transferred to IBM SPSS Statistics 21 (IBM corporation, Armonk, NY, USA) for analysis. Cross-
tabulations were used to determine the relationship between CHWs’ characteristics and 
their responses. Differences between male and female workers were specifically examined 
in relation to demographic and workload characteristics, morbidity management advised to 
patients, and the main problems and solutions related to the provision of care. Comparisons 
were made by odds ratios (OR) with p-values <0.05 as statistically significant. The CHWs’ 
opinions of their training and morbidity management, from additional open-ended 
comments, were highlighted by presenting selected quotes that represented the range of 
opinions put forth.  
5.3 Results  
5.3.1 Demographic and workload characteristics  
In total 61 CHWs across the six upazilas were included in the survey representing 
approximately two to three health workers for each health catchment area. The number of 
respondents per upazila varied for Dimla (n=1), Domar (n=6), Jaldhaka (n=13). Kishoregonj 
(n=5), Sadar (n=21) and Saidpur (n= 15). In total, there were 39 male and 22 female CHWs. 
The average age was 42 years (Range 22-56 years) with the majority (70.5%) in the 41-50 
age-group as shown in figure 6.1. 
Male CHWs were three times more likely to be above the average age of 42 years than female 
health workers (OR=3.22, p=0.045) as shown in table 6.1. Overall, approximately half the 
respondents had primary or secondary level of education (57.4%) or graduate or higher level 
of education (42.6%). Average monthly income for CHWs was 12300 Taka (~GB£=112; 
~US$=149). There was no significant difference between male and female CHWs by 
education and income level. Almost all respondents were Islamic (93.4%) and married 
(96.7%).  
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Figure 5.1 Age distribution of community health workers by sex 
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Table 5.1 Summary of demographic and work load characteristics  
 
Characteristics 
 
Total 
n=61/*59 
 
Male  
n=39 (%) 
 
Female 
n=22(%) 
 
OR 
95% CI 
 
P value 
Age *(n=61) 
    
 
>42 years  43 31 (79.5) 12 (54.5) 3.22 
1.03 - 10.14 
 
< 42 years 18 8 (20.5) 10 (45.5) 0.045** 
 
    
 
Education level (n=61) 
    
 
Graduate  26 17 (43.6) 9 (40.9) 1.12 
0.39 – 3.22 
 
Primary / Secondary (HSC) 35 22 (56.4) 13 (59.1) 0.840 
    
 
 
Income (n=61)      
> 12300 Taka 39 26 (66.2) 13 (59.1) 1.38 
0.47 – 4.08 
 
< 12300 Taka 22 13 (33.3) 9 (40.9) 0.555 
    
 
 
Length of service overall 
(n=61) 
   
 
 
 > 19 years 45 32 (82.1) 13 (59.1) 3.16 
0.97 – 10.29 
 
<19 years 16 7 (17.9) 9 (40.9) 0.056 
    
 
 
MMDP training received 
(n=61) 
   
 
 
Yes 57  38 (97.4) 19 (86.4) 6.0 
0.58 -61.62 
 
No  4  1 (2.6)  3 (13.6) 0.132 
    
 
 
Number of patients in 
catchment (n=61) 
     
> 15 23 19 (48.7) 4 (20) 3.8 
1.07 – 13.4 
 
< 15 38 20 (51.3) 16 (80) 0.038** 
      
Number of patients in last 6 
months * (n=58) 
     
> 10 22 17 (47.2) 5 (27.8) 2.164 
0.65 – 7.19 
 
< 10 36 22 (52.8) 14 (72.2) 0.208 
Patient visit frequency in last 6 
months * (n=59) 
     
> Once 33 21 12 0.778 
0.26 – 2.32 
 
Once  26 18 8 0.653 
      
Average time spent with 
patients * (n=59) 
     
> 20 mins 32 17 (43.6) 15 (75) 0.258 
0.08 – 0.85 
 
< 20mins 27 22 (56.4) 5 (25) 0.026** 
    
 
 
Main location of patient care* 
(n=59) 
     
Home only  27 17 (43.6) 10 (50) 0.77 
0.26 – 2.28 
 
Home and/or clinic, hospital  32 22 (56.4) 10 (50) 0.640 
* Note that 2 health workers reported no patients so were excluded from these analyses   
** p<0.05 
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The average length of time that CHWs were in their health worker position was 19.2 years 
(range 2 to 33 years), with male CHWs found to have a longer service period than female 
CHWs (OR=3.16, p=0.056). The time in the current community position was 9.2 years (range 
1 to 23 years). The vast majority of CHWs (93.4%) had received some form of training on LF 
morbidity management, which was similar between males and females (Table 1). The 
average number of LF patients reported per CHW in their current health catchment area was 
15, with male CHWs reporting significantly more patients than female CHWs (OR = 3.8, p 
value =0.038) (Table 5.1). Two CHWs from Dimla and Jaldhaka upazilas reported no LF 
patients in their catchment, and therefore were excluded from the analysis related to 
patients.  
In the 6 months prior to the survey, two-thirds of CHWs (62.1%) reported they had visited up 
to 10 patients, while around one third had visited more than 10 patients (37.9%). The average 
number of patient visits per month by CHWs was 1.7 times. More than half (56.9%) reported 
that they visited more than once a month, which was similar between male and female 
CHWs. The average time respondents reported to spend with each patient during each visit 
was 20 mins. Overall, more than half of the respondents (55.8%) reported spending more 
than 20 minutes with each patient, with male CHWs reporting spending less than 20 mins 
with patients than female CHWs (OR=0.258, P= 0.026). 
 
5.3.2 Knowledge of disease, prevention and morbidity management  
The majority of CHWs reported the main signs and symptoms of LF as swelling, fever and/or 
rash (and combinations thereof) accounting for 83.6% of the responses. Six respondents cited 
vomiting and diarrhoea, which was not correct. The vast majority (96.7%) identified LF as a 
parasitic disease, which was transmitted by mosquitoes.  When asked about prevention, the 
majority stated that MDA (80.3%) and/or protection from mosquitoes (93.4%) were the main 
methods, but two respondents cited vaccination, which was not correct. In response to 
questions on knowledge of MDA programme 91.8% stated the correct timing and frequency 
of MDA by LF Programme (November every year), but only 60.7% reported both the correct 
drugs and doses, which was similar between males and female CHWs  
All CHWs reported that they identify patients by their clinical conditions, with four health 
workers confirming their diagnosis by conducting ICT card test or night blood test to detect 
microfilaria as part of programmatic activities being conducted in their health facility at the 
time, and seven health workers by obtaining further expert advice from a medical officer. 
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Once the diagnosis was confirmed, CHWs provided either home-based care (45.8%) or a 
combination of home-based management and a referral to a government or private hospital 
(54.2%), which was similar between male and female CHWs.  
The CHWs reported that they advised patients on exercise (96.6%), soap washing (76.3%), 
keeping the leg dry (86.4%), wearing sandals (52.5%), taking medication (69.5%), using 
bandage (20.3%), and surgery for men with hydrocoeles (50.8%), with similar patterns of 
advice given by male and female CHWs as shown in Figure 6.2. When CHWs were asked about 
what additional measures their patients practiced to get relief from their condition, 24 
workers reported that a quarter of the patients reported that they sought treatment from a 
traditional healer (Palli chikistsha; n=15), used a religious based traditional treatment 
(Jharfook; n=6), or cut their skin by knife/fish bone or other type of blade (n=3).  
The great majority of CHWs (94.9%) reported that the government clinics provided the 
necessary supplies for patient care free of charge. When asked about what support was 
provided by the LF programme for patient care, the majority stated that it primarily included 
a combination of the distribution of kit boxes containing a brochure, soap, antibacterial 
/antifungal ointment, bandage, cloth, and training of CHWs and supervisors (94.5%).   
 
Figure 5.2 Morbidity management measures advised by community health workers by sex 
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5.3.3 Opinion on programmatic activities, training and morbidity management  
With regards to MMDP training, the duration was reported to be approximately 7.5 hours, 
and almost all CHWs stated that the training was useful (96.6%). However, when specifically 
asked about the content, duration and practical sessions, most CHWs found the content to 
be inadequate (67.8%), the length of time too short (83.3%) with not enough hands-on 
practical sessions (72.9%). The main suggestion to improve the training was to increase the 
duration (47.5%) and practical aspects (11.9%).  
Selected quotes related to training from individual health workers are as follows; 
Quotes  
We need more training with practical hands-on demonstrations, as well as access to more 
supplies. It would also be useful to raise awareness of MDA and morbidity control. (Female 
Health worker, 47 years) 
Proper training for the health worker and adequate counselling for the patients are important 
for the success of the programme (Male health worker, 46 years)  
We need adequate supplies, build awareness, hands-on training, and an incentive for 
providing morbidity control (Female health worker, 42 years) 
Training and refresher training needs to be done twice in a year (Male health worker, 45 
years) 
It is important to have the involvement of the local community in MDA and to help those 
people affected by filariasis. Need to increase community awareness and incentive for service 
provider (Female health worker, 47 years)  
Need to improve community participation in training and improve incentive (Male health 
worker, 41 years)   
With regards to caring for patients, half of the CHWs (n=30; 50.8%) stated that the time was 
insufficient, with the majority reporting that they were too busy (83.3%) or it was not a 
priority (13.3%). When asked about the measures the LF programme provided (kit boxes and 
training), most of the CHWs (91.5%) stated these helped to improve the condition of the 
patient. Specifically, the CHWs reported that they made patients feel better overall (78.0%), 
reduced their pain (84.7%), frequency of fever and/or ADLAs (42.4%), and the odour of the 
affected limb (35.6%), and enabled them to work longer (40.0%). When asked about caring 
for patients with advanced stage lymphoedema, most CHWs reported that it was difficult to 
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move the limb (71.2%), that patients were unable to wash and dry their limb themselves 
(72.9%), and that improvements in the condition were slow (74.6%). 
Overall, the main problems identified with the provision of morbidity management were the 
lack of adequate supplies (52.5%), no incentive (17.0%) non-cooperation of patient (6.8%) 
and the difficulty in following-up with patients (3.4%). However male CHWs reported the lack 
of adequate supplies for providing care to the patient more of a problem than female CHWs 
(OR 3.2, p= 0.041) as shown in Table 6.2. The main solutions suggested by the CHWs included 
more supplies (61.0%), training (44.1%), efforts to increase awareness in the community 
(55.9%) and combinations thereof, which was similar by male and female CHWs (Table 6.3).  
Selected quotes on patient care from individual health workers are as follows; 
Quotes 
There should be a specialised service for LF patients in local hospitals and it’s important to 
provide good care for poor patients (Male health worker, 45 years) 
More support for transport for the patients to go to the health centre is needed (Female 
health worker, 41 years)  
For hydrocoele patients, there is a need to provide good quality care, support for the 
organisation of surgery and to help reduce the stigmatisation (Male health worker, 43 years) 
It is very important to make a list of all patients and to follow-up every month for necessary 
treatment, advice and medication. Also, some incentive for patients and the health worker 
provider is needed (Male health worker, 43 years) 
Very sick people need more supplies (Male health worker, 45 years) 
Because the filarial affected patients cannot walk so far, they need some support to go to the 
health centre. We also need to conduct vector control and we should provide mosquito nets 
to the poor patients (Male health worker, 45 years)  
With the help of the health worker and after practicing exercises and cleanliness, the patients 
often feel better to walk and work, and they have a better life (Male health worker, 52 years) 
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Table 5.2 Main problem identified with the provision of morbidity management  
Table 5.3 Main solutions suggested to overcome problems with the provision of morbidity 
management  
 
Characteristics* 
 
Total 
N=59 
 
Male  
n=39 (%) 
 
Female 
n=20 (%) 
 
OR 
95% CI 
 
P value 
Adequate supplies 
    
 
Yes  36 24 (61.5) 12 (60.0) 1.07 
(0.35-3.21) 
 
No 23 15 (38.5) 8 (40.0) 0.909 
      
Incentives for home-based 
care 
     
Yes  9 6 (15.4) 3 (15.0) 1.03 
(0.23-4.64) 
 
No 50 33 (84.6) 17 (85.0) 0.969 
      
Training      
Yes  26 17 (43,6) 9 (45.0) 0.94 
(0.319-2.79) 
 
No 33 22 (56.4) 11 (55.0) 0.917 
      
Programme awareness      
Yes  33 23 (59.0) 10 (50.0) 1.44 
(0.486-4.25) 
 
No 26 16 (41.0) 10 (50.0) 0.511 
      
Other      
Yes  1 1 (2.6) 0 (0.0) 1.6 
(0.06 -41.0) 
 
No 58 38 (97.4) 20 (100) 0.777 
      
 
Characteristics 
 
Total 
N=59 
 
Male  
n=39 (%) 
 
Female 
n=20 (%) 
 
OR 
95% CI 
 
P value 
Lack of adequate supplies for 
providing care 
    
 
Yes  31 24 (61.5) 7 (35.0) 3.2 
(1.05-9.74) 
 
No 28 15 (38.5) 14 (65.0) 0.041** 
      
No incentive      
Yes  10 5 (12.8) 5 (25.0) 0.441 
(0.11-1.76) 
 
No 49 34 (87.2) 15 (75.0) 0.245 
      
Non-cooperation of patient       
Yes  4 2 (5.1) 2 (10.0) 0.487 
(0.06-3.74) 
 
No 55 37 (94.9) 18 (90.0) 0.489 
      
Difficult to follow-up      
Yes  2 0 (0.0) 2 (10.0) 0.09 
(0.004-2.05) 
 
No 57 39 (100) 18 (90.0) 0.133 
      
Other      
Yes  12 8 (20.5) 4 (20.0) 1.03 
(0.27-4.0) 
 
No 47 31 (79.5) 16 (80.0) 0.963 
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With regards to the programme in general, when the health workers were asked about the 
LF Programme and elimination, the majority (83.3%) completely agreed with the statement 
“Elimination of filariasis is possible” however, a few health workers (11.5%) said they partially 
disagreed with this statement (but provided no further comment). With regards to MDA 
activities, around one third of CHWs helped to supervise the MDA (35.6%) or prepare the 
reports (30.5%), and stated that most of the community members ingested the drugs. When 
asked about the reasons for individuals not taking the drugs, the CHWs cited that it was 
related to the fear of side effects (13.6%), absence from home at time of MDA (5.1%) or a 
lack of awareness among the community (1.7%). 
 
5.4 Discussion  
This study highlights the important work of CHWs in Nilphamari District, a representative 
endemic region of Bangladesh, providing key insights into their work on LF in terms of 
number of patients they care for, frequency of and time spent during- home visits, MMDP 
training, knowledge of the disease, patient care and advice that they provide, and their other 
programmatic activities and opinions. It provides an important baseline for LF programme in 
which to assess the experiences and perspectives of CHWs over time as the MMDP 
component of the programme develops and expands across all endemic districts in the next 
few years as part the elimination and validation process (WHO, 2017).  
In general, the CHWs were mature and experienced, with the majority in the age range of 
40-50 years and an average length of service of 19 years. Interestingly, about two thirds of 
CHWs included in the survey were male, which may differ to other countries where CHWs 
are predominately female such as in Nepal and Ethiopia and may also have different 
motivations for being a CHW; however, gender differences are not always specifically 
examined (Willis-Shattuck M, et al., 2008, Glenton, et al., 2010, Singh D, et al., 2015). The 
overall workload is an important consideration, and in this current study the CHWs reported 
an average of 15 LF patients each, whom they visited around twice per month for about 20 
mins. Female CHWs reported fewer patients but spent more time with patients than male 
CHWs. The reason for these unexpected significant differences were not explored here in 
depth but should be further investigated; they may be related to the level and setting in each 
of the CHW’s work. Given the age and gender specific distribution of LF morbidity, which is 
most common in those over 50 years of age and differs in presentation by gender, it is also 
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important to assess whether match between age and gender of the CHWs and the patients 
is important in quality of care. 
The findings indicate that many CHWs already had good knowledge of LF and morbidity 
management to inform their practice of LF care. This provides a promising foundation on the 
appropriate knowledge of health workers on filaria, morbidity management, MDA and 
elimination activities in a highly endemic area of the country. Most CHWs demonstrated that 
they have appropriate knowledge in identifying filarial cases with standard procedure and 
suggested the MMDP for their patients as per WHO protocol (WHO, 2013). This contrasts to 
a study in Ghana, which found relatively low levels of knowledge of health professionals and 
community members on LF morbidity (Stanton, et al., 2016). Here, this study also highlighted 
that around one third of the CHWs were also involved in MDA activities, although they could 
not always state the correct drugs and dose required, which may reflect the time elapsed 
since MDA and related training. 
Training provided for CHWs is a day-long course of about 7.5 hours with some hands-on 
practice for morbidity management. Most of the CHWs have been trained on morbidity 
control but they thought that the training was too short, and that the follow-up was not 
frequent enough. Although the knowledge of these experienced CHWs was good, there is 
always room for improvement and refresher training is recommended for all CHWs, but 
especially for new recruits, who may not have a fundamental understanding of LF clinical 
conditions such as lymphoedema and hydrocele. A study in Malaysia found that untrained 
CHWs could not demonstrate appropriate knowledge in terms of case identification and 
morbidity management (AL-Abd, et al., 2014). Systematically and professionally trained CHW 
are a core component of primary health care systems in low resource settings (Singh, at el., 
2015) and it has been shown that well trained CHWs (who work with child health and 
infectious disease) were significantly better at identifying acute illnesses in children and 
increase the cure rate of infected patients in Bangladesh. The current study did not 
investigate the CHW effectiveness, but this would be valuable in future studies.  
Considering the pros and cons of the MMDP programme it was found that CHWs are 
practicing WHO recommended measures such as exercise, elevation, compression, wound 
and skin care, and suitable footwear (WHO, 2013). This is a good base to work from, however, 
a third of CHWs also reported that some of their patients practice unhygienic measures like 
cutting by knife/fish bone, reflecting inappropriate practices as has been noted elsewhere 
(Odhiambo, et al., 2016).  Therefore, it is important to increase effort to investigate any 
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harmful measures and correct those which may harm the condition. A limitation of this study 
is that it did not address the patients’ practice of MMDP, or their concerns and issues related 
to this. Further research is needed to explore the patients’ issues regarding MMDP. 
Nevertheless, the role of frontline health workers such as CHWs cannot be underestimated 
in guiding patients to use safe, effective and quality treatment as emphasised in the WHO 
Dossier requirements (WHO, 2017).   
The CHW is a critical link between the health system and the community members in 
providing knowledge on effective and ineffective or even harmful practices. Educating staff 
and teaching them methods of health promotion helps to ensure utilization of local health 
services for morbidity, and hydrocele surgery in local surgery camps (Stanton et al., 2016). 
The level of community knowledge was not directly studied here, but has been shown by KAP 
study to be quite high in Malaysia (Stanton, et al., 2016) whilst another recent KAP study in 
Nigeria showed that the majority of the community (82%) are not aware about filariasis 
(Amaechi  et al., 2016). 
The strengths of this study are that it is one of the few to provide both quantitative and 
qualitative information by directly interviewing the CHWs, and thus extensively documents 
the workload, knowledge, attitudes and practices of those actually providing community-
based services for home-based management of LF-related morbidity, at baseline before the 
MMDP programme was scaled-up.  A limitation of the study is that the data on average 
number of patients seen and the time spent with them were based on self-report by the 
interviewees, and thus could have been biased, perhaps by overreporting to suggest high 
workload (although there was no incentive to overreport and results were confidential).  It 
was not possible to independently verify these reports in the current study since this would 
require extensive checking with supervisors or patients, but this would be useful to do in 
future work. 
The inability to spend adequate time and follow-up for on-going patient care were identified 
as challenges. This finding is comparable with a recent study on health workers in 
schistosomiasis control in Kenya (Odhiambo et al., 2016). In the current study, the CHWs 
mentioned that they have other prioritized work, which makes their visits infrequent and 
allowing them to only spend a short time with LF patients. However, health workers 
suggested longer training, adequate supplies for patients and spending more time with 
patients might improve the care. Therefore, the programme needs to focus on the 
redistribution of workload, prioritizing morbidity, and providing adequate supplies. This is 
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important in the context of the GPELF, and as the National LF Programme moves towards 
elimination and needs to meet dossier requirements, which include i) data on number of 
patients with lymphoedema and hydrocele, and ii) availability of treatment for lymphoedema 
and hydrocele (Dreyer et al., 2000). 
The CHWs are paid according to Government salary structure, with increases given based on 
length of service and work duration. Only a small proportion of CHWs mentioned incentives, 
which may be related to working extra hours; however, this was not explored in any detail.  
However, some other prioritized programmes that they work on do provide financial 
incentives CHW e.g. immunization, polio eradication, Vitamin A capsule camps, maternal and 
child health care, malaria control and tuberculosis programmes. A study in Kenya suggested 
that incentives might improve performance of CHWs (Odhiambo et al., 2016), and other 
studies elsewhere highlight the CHWs motivations can be multiple and mixed, and vary 
depending on unique social and economic circumstances (Mpembeni  et al., 2015, Burkot et 
al., 2017). Since CHWs are relatively poor, a study in Bangladesh had shown that more than 
80% of CHWs had become a CHW to contribute to the income of their household (Singh  et 
al., 2015).  However, non-cash support and other incentives may also be important in the 
form of supervisory support/appraisals, refresher training, community recognition and 
supplies for patients, and these may be effective incentives as they have shown to improve 
morale, social standing, career development, community approval, and patient care in 
Bangladesh and elsewhere across a range of different health sectors ( Willis-Shattuck et al., 
2008, Signh et al, 2015, Rahman et al., 2010, Alam et al., 2014).  
 
5.5 Conclusion 
Overall, CHWs were well informed on filariasis and the provision of clinical care, indicating a 
good foundation to work from. However, they indicated that they needed more logistical 
support, training and supplies for patients, given the long-term care people with LF morbidity 
require. Insights into their experiences and perspectives helped the LF programme to focus 
on the specific areas that needed improving to optimise health worker training, adjust gender 
workload balance, and improve patient care before the start of the large-scale 
implementation of MMDP activities across endemic areas in 2013. 
 
 
117 
 
Chapter Six 
Key Themes of Lymphatic Filariasis Control and Elimination 
  
 
Bangladesh has interrupted LF transmission after a successful MDA programme over the past 
15 years. This country is now conducting post-MDA surveillance and will transition to the 
elimination phase after all endemic districts have completed of TAS in 2018- 2019. Over the 
next few years as Bangladesh approaches national LF elimination goal, all resources should 
be mobilized to further tackling the morbidity burden and establish sustainable surveillance 
systems which are integrated into health systems. The following key themes should be 
considered for the long-term elimination of LF in Bangladesh and include  
    i) Environment factors inclusive of housing and interplay with vector control options; 
   ii) Personal factors that give light on age, gender of patients as well as community health 
workers; 
   iii) Adherence and compliance with treatment albeit drugs and morbidity reduction tools; 
   iv) Household level factors such as co-impact of disease disability in other family members. 
. 
6.1 Environmental factors 
The levels of LF endemicity across the country may be related to key environmental factors 
including demographics, housing structure and mosquito vector species. The highest baseline 
prevalence rates and case numbers was found in the northern region, Rangpur Division 
(Shamsuzaman et al, 2017), which is very rural and one of the poorest areas in Bangladesh 
(BBS, 2011). The high levels of poverty among people in the is region indicate that the 
infrastructure of housing, health and communities may be less than adequate to protect 
them from high levels of transmission. As found in other vector-borne disease studies, good 
housing with closed ceilings, window nets or curtains and other barriers to mosquito bites 
can reduce the chance of being infected and developing the disease (Haque et al, 2014).  In 
Bangladesh the main LF mosquito is Culex quinquefasciatus, which is very prevalent and has 
adapted well to the human environment, especially areas where there is dirty polluted 
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water.in poor areas with poor drainage (Stillwaggon, et al, 2016). This makes it difficult to 
control and the LF programme could aim to improve its public health awareness of this link 
with the local environment, open housing and drainage system so people are aware how to 
reduce being bitten and allowing the transmission to return. 
Although MDA is effective in interrupting LF transmission, vector control can be a 
supplementary intervention to block the transmission cycle (Moses et al, 2009). Vector 
control is one of the strategy to control all vector-borne diseases. In Bangladesh, there are 
several diseases that are co-endemic, for example malaria and Kalazar. In these areas vector 
control strategies like insecticide impregnated mosquito net, indoor residual spraying of 
insecticides are implemented in many endemic districts by malaria control programme 
(Haque et al, 2014). However, as the Culex mosquitoes that transmits LF is different to other 
vectors in Bangladesh, there is limited opportunity to coordinate or integrate vector control 
programmes, for example the geographical distribution of LF and malaria do not overlap at 
all in Bangladesh (Haque et al, 2014). However, it may be possible for some components of 
the LF elimination programme be integrated with the mainstream malaria control 
programme, which could extend its work to key LF areas or hotspots (i.e. areas of ongoing 
transmission). Already there is a wide distribution of mosquito nets outside the malaria 
endemic areas. This is mainly due to the nuisance biting factor associated with Culex and 
other mosquito species with many people purchasing their own nets. While this study did 
not examine vector control for LF elimination, the LF programme could better link with the 
other vector control programmes, to help maintain awareness of the ongoing risks, share 
public awareness resources and implement targeted control if necessary to help stop 
transmission in the long-term. 
 
6.2 Personal factors  
In additional, it will be important to consider factors related to long-term morbidity 
management and how the health system can integrate patient care into the existing 
infrastructure. Personal factors related to age, gender of patients and health workers may be 
key elements to considered for the long-term sustained reduction in the number of clinical 
cases and improvement in clinical conditions and patients’ quality of life. There is an 
emerging story of disability and the impact the physical manifestations of LF make on daily 
activities and participation in community life (Zeldenryk et al., 2011). This study revealed the 
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gender differences of disability in male and females but did not examine in any detail the 
impact on day to day activities and social life. This is an important area for further research 
and something that the GPELF could further support or highlight together with the standard 
morbidity management activities it promotes (WHO MMDP, 2013).   
 
The most of affected people found in this study were adults and elderly people, who would 
have been affected for many years or decades. Hydrocele and lymphoedema lead to long-
term and permanent disability (WHO, 2013), and as a result would have had a devastating 
effect on their personal, economic and social life (Stillwaggon economic lymphoedema paper 
refs). For males, hydrocele is a severe form of disability leading to social stigmatization and 
physical limitation. For females, lymphoedema, elephantiasis and genital swelling is also 
associated with shame and taboos, and may make it impossible to get married, which is an 
essential source of financial and social security in Bangladesh (BBS, 2011. Further research 
could be done to assess psychosocial impact of permanent disability, and the LF programme 
should work towards raising awareness of this disease and also engage males and female 
health workers to help deliver the care to patients.  
 
Given the high number of older male health workers found in this study, it may be more 
effective if male health workers specifically targeted men with hydrocoele and helped to 
refer them for surgery. This may help to overcome any stigma or shame associated with the 
conditions and increase the uptake of surgeries. Currently, the LF programme is having 
difficulty in scaling up the surgeries across the highly endemic areas, so this could be an 
important role for male health workers, who seem to be older and therefore may get more 
respect. Similarly, it may be more appropriate if female health workers focus on female 
patients to help overcome any barriers or shame in receiving treatment. While this gender-
based concept is not ideal and may not be practical everywhere, in some circumstances it 
may be effective and help reduce the pain and suffering. In rural area women health workers 
are readily accepted by affected women especially when it involves in private parts. However, 
this area need to be explored. 
 
In Bangladesh, the morbidity management control programme has been underway since 
2013 and primarily involves providing training and refresher training to a variety of health 
workers, as well as hydrocoele referrals and surgeries, and basic wash kits for lymphoedema 
management (MOHFW, 2010). However, as this study found, prior to this MMDP work 
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starting, there were some unhygienic practices being undertaken by patients, though in low 
numbers.  Interestingly, females were most likely to use more traditional healing strategies 
e.g. Jharfoak, the religious-based traditional healing method which does not use any 
substances. Several other alternative and potentially dangerous practices were being used 
like cutting of oedematous leg by knife and fish bone. In spite of available modern medical 
services in rural areas of Bangladesh, the rural community has more tendency to seek 
treatment from traditional healers (Haque et al., 2018). Not only for LF, the traditional 
healing has been widely practiced as the means of primary healthcare in rural areas of 
Bangladesh, especially among the people with low socioeconomic status. The extent of use 
of alternative services has shown not to decline with the advancement of modern medical 
sciences (Haque et al., 2018), which could also have implications for the LF programme. In 
this context, LF programme needs to focus on maintaining all health care services for LF 
morbidity control as well as raising awareness of the public about these services to ensure 
that the patients are aware of and receive the best care possible. 
 
6.3 Adherence and compliance with treatment 
Adherence and compliance with treatment is a key to success of LF elimination as highlighted 
by the WHO (WHO Weekly Epidemiology Report, 2017). This is important for both MDA and 
MMDP activities. Bangladesh has been successful in getting high drug coverage to the 
majority of people at risk, enabling the interruption of transmission (Shamsuzzamans et al, 
2016), and as a consequence has put the country on track to reach the elimination goal of 
2020 (WHO, 2016). However, adherence to morbidity control may be a long-term challenge 
due to a lack of awareness and motivation for regular self-care if patients do not receive the 
appropriate training or any continuous supervision. There may also be self-stigma and shame 
related issues which are barriers for patients. It will be important for the LF programme to 
maintain adequate training, logistics and supplies or patients so that compliance is 
maintained. Gender sensitive awareness campaigns may be effective e.g. engaging with local 
community male leaders, or TV and Radio campaigns for hydrocele surgery while door to 
door visits for lymphoedema for females.  
For lymphoedema management, the best morbidity reduction tools include basic supplies 
and materials for care e.g. soap, cloths, basin, antifungal cream, appropriate footwear, access 
to transport, access to health services and knowledge of general and personal hygiene 
measures (WHO- MMDP, 2018). Perhaps most importantly, it will be essential for patients to 
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ensure that there is a water supply available.as hygiene is a vital factor for preventing ADLAs 
and progression of disease.  This is a cost- effective method which most patients can afford. 
Severe cases of lymphoedema sometime require antibiotics to address the localised 
infections and ADLA impact. There is little literature on the extent to which patients use 
antibiotics (Stanton et al, 2015, Martindale et al, 2017 Malawi). However, the use of 
doxycycline is becoming increasing important as it has shown to impact on LF conditions 
(Mand et al, 2012). A few recent studies explored that people may prefer 8 weeks 
Doxycycline daily doses than hydrocele surgery. However, there is a question of compliance 
for 8 weeks medication (Stanton et al, 2016). At present the regular use of doxycycline is not 
a WHO recommendation, and its large-scale use would need to be monitored carefully, 
especially for women of child bearing age where felt abnormalities could occur. 
 
6.4 Household factors 
The direct economic cost related to the acute and chronic manifestations of LF are a burden 
on the patient as well as their families, caregivers and the wider community, especially in 
high burdened areas such as Rangpur Division. There is very little research on the wider 
impact, especially in relation to families and caregivers. One small study in Malawi found that 
females were the main caregivers of men with hydrocoele and that their lives were impacted 
socially and economically, but improved after surgery (Martindale et al, 2017).  It is estimated 
that the cost of treating ADLA episodes ranges from US$ 0.25-1.62, which is almost two days 
wages in some countries. While the cost of hydrocele surgery, depending on source of care, 
is estimated to be around US$ 5-60 (Addiss et al., 2007). Economic and social implication of 
such a high burden with long-term disability has not only physical implication but economic 
and social implications as it means that people cannot lead productive lives. It affects their 
mental well-being as well and estimates of mental illness have been recently highlighted in 
Ton et al. paper (Ton et al, 2015).  Overall, men are significantly burdened by hydrocele which 
may impact on their ability to provide economic support for their family. This has significant 
implications and a major barrier to getting out of the poverty cycle, and women and children 
may need to work more to help the family make a living. The economic impact of these 
conditions needs to be better quantified. Furthermore, the WHO and other researchers 
suggested that that poverty and NTDs are interrelated (WHO, 2013; Zeldenryk et al.,2013). 
Therefore, more research needs to be done on the specific issues. 
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Conclusion   
This thesis has highlighted the burden and changing epidemiology of LF, the different aspects 
of the community knowledge, attitude and practice of LF, and the importance of training and 
maintaining a health work force to address both transmission and morbidity control in the 
long-term. This is important and the environment, personal, adherence and household 
factors should be taken into account, especially as Bangladesh progresses towards the LF 
elimination goal of 2020.  
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Chapter Seven 
Recommendations 
 
7. Recommendations  
7.1 Programmatic recommendations  
⎯ To ensure that there are adequate resourced health centres in the most endemic areas 
of each district with well trained staff for all aspect of lymphoedema care, but also 
referral system in place specially for hydrocele surgery.  
⎯ To ensure that there is specific morbidity management training among health workers 
to deliver appropriate care to male and female patients and their specific clinical 
conditions.   
⎯ To determine how hydrocoele surgeries can be scaled up to address the immense 
burden in some communities. 
⎯ To ensure that community awareness is maintained, and appropriate materials are 
supplied to enhance social mobilisation and to help overcome stigma related issues. 
⎯ To work to develop health worker curriculums to improve training, including practical 
hands-on demonstrations of lymphoedema care. 
⎯ To establish a simple sustainable method for monitoring the reduction in case numbers 
over time to ensure that the burden of disease will eventually reduce to zero. 
⎯ To determine potential programmatic linkages with different vector-borne disease 
control programmes to enhance long-term surveillance opportunities.  
 
7.2 Research recommendations  
⎯ To determine what are the most important demographic and environmental risk 
factors associated with the hotspots of disease.  
⎯ To follow-up patients from baseline study and determine the impact of MDA and 
other interventions on their conditions e.g. people with stage 1 lymphoedema in 
2005 – did it progress and worsen, or did it stay the same with the introduction of 
MDA. 
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⎯ To determine if the cluster survey methods reflects the true burden of disease or if 
there are other methods to use that may be more cost effective to get disease 
burden estimates.  
⎯ To assess psychosocial impact of permanent disability associated with LF clinical 
conditions 
⎯ To determine impact of clinical disease and disability on the mental health of patients 
and their families and caregivers, and how this changes as people’s conditions 
improve.  
⎯ To determine the roles of community leaders in increasing knowledge of LF and how 
to encourage them to involve in community awareness programme.   
⎯ To understand the stigma related issues of LF and how it may affect the peoples 
economic and social life. 
⎯ To examine the relationship between poverty and disease 
⎯ To determine what specific training and specialised knowledge and care is required 
for severe case management   
⎯ To determine if a more gender-based division of care (i.e. male health workers 
predominately look after male patients and female health worker predominately 
look after male patients) would improve uptake of surgeries for men and 
lymphoedema management of all patients 
⎯ To better understand and document the alternative practices e.g. cutting/knife, that 
people use for relief of their condition and the potential damage they may cause. 
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Appendices  
 
 
Appendix I Consent for household survey. 
 Liverpool School of Tropical Medicine (LSTM), University of Liverpool, UK 
Consent form for household survey and knowledge, attitude and practice (KAP) study 
 
Informed Consent 
Title of Research:  Extent of lymphedema and morbidity management in lymphatic filariasis 
endemic areas of Bangladesh. 
Principal Investigator: Dr Israt Hafiz, PhD student of Liverpool School of Tropical Medicine 
LSTM, University of Liverpool, UK  
Participating Institutes  
Centre for Neglected Tropical Diseases, Liverpool School of Tropical Medicine, UK;  
Directorate General of Health Services, Ministry of Health and Family Welfare, Bangladesh. 
 
You are being asked to take part in this study because you may be at risk of a disease called 
lymphatic filariasis (also known as elephantiasis), which can cause swelling in your limbs and 
other body parts. Before agreeing to participate in this research study, it is important that 
you read (or someone read for you) the following explanation. Please take your time to make 
your decision.   
 
Why is the study being done? 
The overall aim of this study is to find out how much leg swelling and other signs of Lymphatic 
Filariasis, people have in areas of Bangladesh. This research will find out the magnitude of 
problem and knowledge, attitude and current practices of the community to manage the 
problem. The results will help to plan and design the appropriate ways to control problem of 
the disease.  
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Reasons for being selected for the interview? 
Since you are a resident of the Lymphatic Filariasis endemic area, we would like to request you 
to help us by participating in the study. 
 
How many people will take part in the study? 
Overall, there will be about 1300 people from 300 households involved in the study from 
communities of Nilphamari district in Bangladesh. In your community there will be about 10 
households and 50 people involved. 
 
What is involved in the study? 
There are two parts of the study. These are: 
i)  Morbidity/clinical [and infection] survey  
ii) Knowledge, attitude and practice (KAP) household survey. 
1. The morbidity survey will help to detect filariasis affected people with swollen leg, arm, 
scrotum and with other parts of body severely affected. We will examine you and 
family members so we can see how many people are affected. If you have any clinical 
disease, we would also like photograph it (with your permission) for our records. 
 
2. About 50% of population will be tested to see infection. If your household is selected, your 
blood will be tested for infection. We will test for infection with rapid ICT card test by 
taking a few drops of blood by finger prick. This ICT test does not tell us if you have a 
current infection, so if you show positive, we will do another test to detect if the filaria 
worms are in your blood. This test is called a microfilaria (mf) test, which will need to 
done at night and will also involve taking a small drop of blood from your finger. The 
reason why we have to do this test is because the filaria worms are active at night and 
can only be detected after 10pm. It is important to do as it shows if you have a current 
infection. This test will be done once, and if positive, you will be offered standard drug 
treatment and information on preventive measures. 
 
3. All people who will have any swelling in legs, arms, breast & genitalia, will be asked to 
participate in a knowledge, attitude and current practices study about the filariasis, its 
problem and how to solve/manage the problem. In absence of patients with swelling 
a caregiver (If there is any) will be asked to participate in this part of study.  
How long will you/your family be involved in the study? 
The whole study will last for two years; however, the part that you are involved in will take 
about half an hour to complete the surveys.   
What are the risks of the study? 
The risk from participation in this study is very minimal. Finger prick to test filaraisis infection 
may cause transient pain which will be well tolerated by all. To reduce the risk all aseptic 
measures will be taken and standard operative procedure will be practiced. 
 
What are the benefits of the study? 
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Overall, the study will show the current status of disease burden of swelling of legs, arms and 
genitalia. It will also identify the knowledge, attitude and perception on management of the 
problem which will help to design the future program suitable for the community.  
 
What are the incentives? 
You will not be provided any incentive to take part in the research. 
 
What about confidentiality? 
Your name and other personal data from the study will remain confidential. Only a code 
number will be used during data entry. The overall results will be published for scientific 
purposes. The participants’ identity will not be revealed. Only researchers from the study will 
have access to the study data. All study results and information will be kept in a secure 
location of PhD project office. For computer copy, a password will be used to secure 
confidentiality. 
 
What are the costs? 
There will be no costs for participating in the research. To manage the study, all required 
logistics will be provided free of cost. There will be no personal investment except 
participating in the study.  
 
Right to refuse or withdraw 
Your participation is entirely voluntary. You may withdraw from this study any time without 
any hassle or loss of benefits. 
 
Who do you contact if you have a question or problem? 
 Dr Israt Hafiz, Technical consultant, Filariasis Elimination Program, DGHS, Dhaka, Bangladesh   
Telephone 88 01552415070, 88 02 9354138 and the Chairperson, Bangladesh Medical 
Research Council (BMRC), Mohakhali, Dhaka. Bangladesh 
 
Do you agree to participate?  Yes [  ]   No [  ] 
I acknowledge that this consent form has been fully explained to me in a language that I 
understand and I agree to participate in the following parts of the study.  
 
                           Morbidity survey for lymphodema (clinical examination) 
              Household survey (KAP) 
                            Infection survey (ICT/Mf) 
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Participant’s name: 
________________________________________________________________ 
 
Participant’s signature (or thumb print):_______________________________ Date: 
___/___/___ 
 
(or legal guardian if participant is a minor – note relationship). 
____________________________ 
 
Name and signature of witness  
________________________________________________________________Date:___/__
_/__ 
 
Printed name of person obtaining Consent  
________________________________________________ 
 
Signature of person obtaining consent 
 Date: ___/___/___ 
(Must be study investigator or individual who has been designated to obtain consent) 
  
Appendix ii – part a: Case record form to determine the clinical cases with stages 
Interviewer code |__|__|     
Upazila   ___________________ |__|__|__|__|                   
Village   ___________________ |__|__|__|__|                  House Number   |__|__|   
Code of House______________ |__|__|__| 
1. Name of head of household: ................................................2. No of Family members.................................................................................. 
3.  Marital status………………………………………………… 
4. .Average monthly expenditure……………………………………….. 
 
 CHECK ALL THAT APPLY 
 List of family members (> 10 yrs old) with details of affected part of lymphedema: 
Sl  no. Code 
Number 
Name Age (yr)  Sex 
M-00, F-
01 
Leg Arm Hydrocel
e (i-ii)** 
Breast Genital 
organ 
Combina
tion 
Stage (i-vii)* ICT test 
result 
00-+ve, 
01--ve 
Mf in night 
blood sample 
00-+ve,01--ve 
R L R L R L 
          
1.                
 
  
2.                
 
  
3.                
 
  
4.                
 
  
5.                  
*Stages of leg swelling 
** Stages of Hydrocele
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Appendix iii- part b. Questionnaire to determine the stage of lymphedema 
Name: 
Code number: 
(Dreyer staging of lymphedema) 
Clinical questions for lymphedema patients 
 Left leg Right leg 
1.What is the stages of Lymphoedema     
   Is swelling reversible over night? 
     (reversible swelling; disappear  
     spontaneously overnight) 
Y N Y N 
 Are there shallow skin folds? 
     (base of fold is visible when patient moves the 
legs) 
Y N Y N 
Are knobs present? 
 (knobs, humps, lamp or protrusions of skin) 
Y N Y N 
Are there deep skin folds? 
   (base of fold is visible when separated by hands) 
Y N Y N 
Are mossy lesion present? 
(mossy lesion; cluster of small growth on the skin 
with wart like appearance usually on foot) 
Y N Y N 
2. Drayer stage of lymphedema (using staging chart 
and features from above) 
# Left leg=           # Right leg= 
Y N Y N 
3. Is patient having acute attack currently? 
   (acute attack or filarial fever; episodes of acute  
   inflammation, pain, redness and swelling in limb 
   with associated lymph nodes (Kernals) ague and 
   fever 
Y N   
4. How many acute attacks have occurred in past 6 
    months? 
    None   1    2    3    4    5    >5 
 
    
4a. How long do the acute attack usually last? 
     1   2  3  4   5   6  7   > 7 days 
    
5. Are there ‘entry lesions’ present at any site on the 
   foot? 
   (entry lesion; break in surface of skin; these may 
   be round, ulcer, cracks or sores)  
    
6. Are interdigital lesions present? 
   (interdigital lesion; abnormal skin in web space  
   between toes; this can be saggy skin or scaly skin) 
   Left foot                   Right foot 
   4   3   2   1                1  2  3  4 
Y N   
7. Nature of interdigital lesion 
  Is skin scaling? (scaling; skin is dry with 
 
Y 
 
N 
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Extra 
notes/comments:____________________________________________________ 
Grading or staging of lymphedema legs 
 (A) Stage 2, swelling that is not reversible overnight. 
(B) Stage 3, shallow skin folds at the ankle. 
(C) Stage 4, alteration of skin texture and formation of knobs (arrowheads). 
(D) Stage 5, presentation of deep skin folds in addition to the alterations of stage 4; 
(E) Stage 6, presentation of mossy lesion in addition to the alterations of stage 5. 
(F) Stage 7, inability of patient to perform daily work. 
Picture demonstrating Dreyer staging: 
 
 
 
 
 
 
 
 
 
(Source Dreyer et al, 2000) 
  superficial scale) 
  Is skin peeling? (peeling; surface of skin peeling  
  away)  
  Is skin cracking? (cracking; breaks in skin surface) 
  Is skin macerated? (0macerated; area is moist and 
   erosive) 
  Is there a bad odor?  
  Is area painful? 
  Is area itchy? 
 
Y 
 
Y 
 
Y 
Y 
Y 
Y 
 
 
N 
 
N 
 
N 
N 
N 
N 
 
8. Color of lesions? (order; fresh colored,   white,  
    other color,     please specify....................... 
    
9. Are any nails dystrophic? (dystrophic nails; 
    thickened and/or discoloured) 
   Circle nail that are abnormal 
     Left foot             Right foot 
   5   4   3   2   1       1  2   3   4   5  
Y N   
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Thank you very much for your cooperation 
 
Appendix iv. Questionnaire for KAP study on lymphatic filariasis and morbidity management  
 
KAP study on lymphatic filariasis morbidity 
Interviewer |__|__|    District  ______________________ |__|__| 
Upazila   ___________________ |__|__|__|__|                   
Village   ___________________ |__|__|__|__|                    
Household Code Number ______________ |__|__|__| 
Individual Code Number ______________ |__|__|__| 
CHECK ALL THAT APPLY 
   
  
Q No. Question Answer Response 
1 Sociodemographic information  |__|__| 
1.1 Sex 0-Male 
1-Female 
|__|__| 
1.2 How old are you?  ........................       years |__|__| 
1.3 What do you do (Occupation)?  
 
 
00-Agriculture  
01-Service 
02-Business  
03-Day labour 
04-skilled labour 
05-Housewife 
06-Student  
88-Other 
|__|__| 
 
 
……………………
…… 
1.4 At which level you have 
completed your education?  
 
Completed year of education 
01- Illiterate/no school ……….. 
02- Non formal  
03- Other, Please 
specify…………………………… 
|__|__| 
 
……………………
…… 
1.5 Religion 00-Islam 
01- Buddhism 
02- Hinduism 
03-Christianism 
88-Other, Please specify ………………………. 
|__|__| 
1.6 Tell me about your marital status? 00-Unmarried 
01-Married 
02- Divorced  
03-Widow 
|__|__| 
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88-Other……………………… 
2 KAP on morbidity   
2.1 Have you heard of lymphatic 
filariasis (or ‘Goad Roag’)? 
00-No  
01-Yes 
|__|__| 
2.2 From where did you know about 
Filariasis 
Media No-0 Yes-1 
Health assistant   
Doctor   
Radio   
TV   
Newspaper   
Friends/Neighbou
r 
  
Folder   
Miking   
 
 
2.3 What type of disease Filarias is ? 1. Infectious 
2. 1-Hereditary 
3. Tumerous/cancerous 
4. From bad air 
88- Other, Please specify 
90- Don’t know 
|__|__| 
2.4 What are the main symptoms? 
 
Symptoms No-0 Yes-1 
Pain   
Fever   
Articaria   
Vomiting/Diarrhoe
a 
  
Gradual swelling of 
body parts 
  
88-Other, Please 
specify 
 
90-Don’t know  
 
 
2.5 How is it transmitted from one 
person to another? 
00- Food/ water  
01- Personal contact 
02- Mosquito bite  
03-Cough 
88-Other please 
specify…………………………... 
90- Don’t know 
|__|__| 
I will ask some questions about Filariasis where different people have different opinion. I want to 
know your opinion 
2.6 ‘Filariasis is spread by personal 
contact’- What is your opinion 
on this? 
0-completely agree 
1-partialy agree 
2-partialy disagree 
3-completely disagree 
90-Don’t know 
|__|__| 
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2.7 Filariasis is a result of curse ? 0-completely agree 
1-partialy agree 
2-partialy disagree 
3-completely disagree 
90-Don’t know 
|__|__| 
2.8 Filariasis is transmitted to other 
staying in same house. 
0-completely agree 
1-partialy agree 
2-partialy disagree 
3-completely disagree 
90-Don’t know 
|__|__| 
2.9 Filariasis is caused by bad air. 0-completely agree 
1-partialy agree 
2-partialy disagree 
3-completely disagree 
90-Don’t know 
|__|__| 
2.10 Filariasis is a curable disease. 0-completely agree 
1-partialy agree 
2-partialy disagree 
3-completely disagree 
90-Don’t know 
|__|__| 
2.11 It can be prevented by 
vaccination. 
0-completely agree 
1-partialy agree 
2-partialy disagree 
3-completely disagree 
90-Don’t know 
|__|__| 
2.12 Elimination of Filariasis is 
possible. 
0-completely agree 
1-partialy agree 
2-partialy disagree 
3-completely disagree 
90-Don’t know 
|__|__| 
2.13 Is there anybody in your house 
who have swollen 
legs/scrotum/breast/genitalia 
(lymphedema)? 
00-No  
01-Yes 
 
 
|__|__| 
2.14 What do you know about 
management of this disease? 
0-taking medicine once ina year for 
subsequent 5 years 
1-Taking medicine once in a year is enough 
2-It is not curable by treatment 
88- Other, please specify 
90-Don’t know 
|__|__| 
2.15 From where you get 
treatment? 
0-Health Assistant gives medicines at 
home 
1. Local health centre 
2. Private hospital 
3. Community clinic 
88- Other, Please specify… 
90-Don’t know 
|__|__| 
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2.16 How do you get medicine ? 1. Govt supplies free of cost. 
2. Buy yourself 
88-Other, please specify.. 
|__|__| 
2.17 How do you think the 
occurrence of the condition 
(filariasis) could be prevented? 
Preventive measures No-0 Yes-1 
Taking yearly medicine 
distributed to the 
community by health 
worker 
  
By protecting from 
mosquito bite 
  
Take medicine from 
clinic/hospital 
  
-By vaccination   
88-Other please specify …………….. 
90-Don’t know  
-  
|__|__| 
2.18 What preventive measures 
were taken in your area? 
Preventive measures No-0 Yes-1 
Distributing yearly 
medicine to the 
community by the health 
workers 
  
Protection from 
mosquito bite 
  
Using mosquito net   
Insecticide for mosquito   
Vaccination   
88-Other please specify …………….. 
90-Don’t know  
 
 
2.19 During the last 5 years, how 
many times did you take the 
medicine distributed in the 
village? 
 |__|__| 
2.20 Why did you take medicine? 1. HA advised to take medicine 
2. Doctor advised 
3. Convinced by camping of Radio/TV 
4. Aware of prevention of disease 
5. Concern about spreading of 
disease 
6. For prevention of disease in future 
generation 
      90- Don’t know 
|__|__| 
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2.21 Had you have any problem 
after taking medicines? 
00-No  
01-Yes 
 
 
|__|__| 
2.22 If faced problem, what type of 
side effects had you have? 
Side effects No-0 Yes-1 
Itching   
Articaria (rash)   
Pain in abdomen   
Nausea   
Diarrhoea   
88-Other, please specify  
 
|__|__| 
2.23 If not taken medicine, what are 
the reasons for not taking the 
medicine? 
 
 
00-Don’t get medicine 
01-Absent at home during drug 
distribution 
02-Fear of side effects 
03-Don’t know why they should take 
drug/lack of awareness 
88-Other……………………….. 
89-.None 
|__|__| 
2.24 From where you know about 
distribution of medicine? 
0-Folder/Leaflet/Poster 
1-HA 
2-Radio 
3-TV 
4-Newspaper 
5-Friends 
6-Miking 
88-Other, Please specify 
|__|__| 
2.25 Do you take any measures to 
protect yourself from mosquito 
bite? 
00-No  
01-Yes 
|__|__| 
2.26 If yes, what are the measures 
do you use? 
 
Protection from 
mosquito bite 
No-0 Yes-1 
Mosquito/ bed net   
Coil   
Spray   
Electrical 
coil/measures 
  
To clean surrounding   
88- Other, please 
specify.. 
  
90-Don’t know   
 
 
2.27 Do you have mosquito net? 00-No  
01-Yes 
|__|__| 
2.28 If yes, do you always sleep 
under mosquito net? 
00-No  
01-Yes 
|__|__| 
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2.29 Anyone else in the house does 
sleep under the mosquito net? 
00-No  
01-Yes 
 
|__|__| 
Applicable for patient only 
3.1 What are the problems do 
you feel other than 
swelling ? 
 
 
Problems No-0 Yes-1 
Pain   
Redness of affected limb   
Bad odor   
88-Other, please specify   
89-none   
|__|__| 
3.2 What are the problems do 
you feel due to swelling 
 
Problems No-0 Yes-1 
Look odd   
Feel heaviness   
Difficulty in walking   
Feeling sad/depressed   
Social stigma/nobody 
want to talk to me 
  
88-Other, please specify   
89-none   
 
3.3 Have you faced any social 
problem for this? 
1. Divorce 
2. Separated 
3. Isolation 
88- Other 
89- None 
|__|__| 
3.4 Do you feel any difficulty 
to do household activities 
with swollen parts ? 
00-No  
01-Yes 
02-can’t understand 
 
|__|__| 
3.5 Do you feel any difficulty 
to move around with 
swollen parts ? 
00-No  
01-Yes 
02-can’t understand 
 
|__|__| 
3.6 Do you feel difficulty to 
work in workplace with 
this condition? 
00-No  
01-Yes 
 
|__|__| 
3.7 What measures are you 
practicing to get relief 
from your health condition 
(filariasis)? 
Measures taken Never-0 Do 
regularly-1 
Do 
someti
mes 
Leg elevation    
|__|__| 
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Exercise    
Wash with soap    
Sandel    
Cleaning    
Bandage    
Use medicine    
88-Other    
89- none    
 
3.8 What type of problem do 
you face?  
01-Work fewer hours/reduced activities 
02-Not able to do certain kind of activities/Not 
able to do heavy work 
03- Stop or change the occupation 
04-Not able to work at all 
88- other 
|__|__| 
3.9 Are you taking any other 
measures without advise 
of doctors /HA ? 
00-Cutting with knife/fish bone 
01- Jhar-foak 
02-Local traditional measures by Gipsy 
88-Other, please specify…………………………. 
89-.None 
|__|__| 
3.10 How long are you using the 
measure?  
 |__|__|  
Month 
3.11 Are these measures 
helpful for you ? How 
much improvement did 
you notice ? 
0-No improvement at all 
1-A little bit improvement 
2-Overall improvement 
3-Improved a lot 
|__|__| 
3.12 What type of 
improvement did you 
notice by practicing these 
measures?  
Improvements No-0 Yes-1 
It improves working hours 
per day 
  
Reduce swelling   
Relief pain   
Reduce frequency of 
fever/Acute episodes 
  
Leg or affected organ 
remains clean/odourless 
  
Overall, feels better   
No relief   
88-other………………………….   
89-.None   
 
 
3.13 How easy or difficult to 
practice these measures? 
00-Very easy 
01-Somewhat easy 
02-Somewhat difficult 
03- Very difficult 
90-Don’t know 
|__|__| 
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3.14 Have you had any training 
from health staff to 
manage your swollen 
limb? 
00-No  
01-Yes 
|__|__| 
3.15 What supplies were given 
to you for your condition 
from Government? 
00-Brochure 
01-Soap 
02-Ointment 
03-Bandage cloth 
88-Other………………………….. 
89-None 
|__|__| 
3.16 Do you find these things 
are useful for you? 
00-Useful 
01- Not useful 
02-Don’t like 
03-Don’t know how to use 
04-Better to buy yourself 
|__|__| 
3.17 Do you know about free 
Medicine distribution by 
government in your 
community? If answer is 
‘No’, go to Q 2.17 
00-No  
01-Yes 
 
|__|__| 
Applicable for Hydrocele patient 
3.18 Do you know about the 
treatment for hydrocele? 
00-No treatment  
01-Surgical treatment 
90- Don’t know 
|__|__| 
3.19 In case of scrotal swelling 
have you undergone 
surgery for hydrocele? 
(patient with scrotal 
swelling only) 
00-No  
01-Yes 
|__|__| 
3.20 If not, why don’t you take 
surgical treatment ?  
0-fear of side effect 
1-Lack of awareness 
2-no facility at local centre 
3-Expansive 
88-Other 
89- none 
|__|__| 
 
Thank you very much 
 
 
                                                               ******************* 
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Appendix v: Questionnaire to assess the extent of work of community health workers and their 
management of LF patient. 
 
Liverpool School of Tropical Medicine (LSTM), University of Liverpool, UK  
Title of Study: Extent of lymphedema and morbidity management in a lymphatic filariasis endemic area of 
Bangladesh 
Appendix 5  
 
Questionnaire for Community Health Workers (CHW) 
 Interviewer |__|__|    Upazila   ___________________ |__|__|__|__|                    
Code number of service provider ______________ |__|__|__| 
CHECK ALL THAT APPLY 
           
Q No. 
Question Answer Response 
1 General information   
1.1 Sex 01- Male 
02- Female 
|__|__| 
1.2 How old are you?  ........................       years |__|__| 
1.3 At which level you have 
completed your education?  
 
00-Primary 
01-SSC 
02-HSC 
 03-Graduate 
 04-Postgraduate 
 05-Vocational 
 06-Iliterate 
 88-Other 
|__|__| 
1.4 Religion 00-Islam 
02- Buddhism 
03- Hindu 
04-Cristian 
88-others 
|__|__| 
1.5 Marital status 00- Single  
01- Married 
02- Separated 
03- Divorced 
04- Widow…………………… 
|__|__| 
 
1.6 Monthly expenditure of 
households (taka)  
……………………. 
…………………….. 
|__|__| 
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1.7 How long have you been 
working (months) in this job? 
 |__|__| 
1.8 How long have you been 
working in this community? 
 |__|__| 
2 Questions related to lymphatic filariasis morbidity management 
2.1 How many patients do you 
have in your working area? 
 |__|__| 
2.2 How did you diagnose them 
as filaria patients? 
 
Process of identify No-
0  
Yes-1 
Identifying 
symptoms 
  
Night blood test   
ICT card test   
According to Dr’s 
diagnosis 
  
Other   
 
 
2.3 What are the main symptoms 
of this disease? 
 
 
Symptoms No-
0  
Yes
-1 
Fever   
Rashes on body   
Vomiting & Diarrhoea   
Gradual swelling of 
different parts of body 
  
88- Other   
90- don’t know   
 
 
2.4 What type of disease is it? 00-Parasitic 
01-From bad air 
02-bacteria borne 
88-Other ………………………….. 
90-Don’t know 
 
2.5 What causes lymphatic 
filariasis? 
00- Food/ water  
01- Personal contact 
02- Mosquito bite  
03-Cough 
88-Other………………………….. 
90- Don’t know 
|__|__| 
2.6 What do you do for patents 
after diagnosis? 
00-advice to care affected limbs at 
home 
01-refer to govt hospital for care 
02- refer to private hospital for care 
88-Other 
|__|__| 
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90- Don’t know 
2.7 Where do you give care for 
patients? 
00- At home 
01- Govt Hospital 
02- Community clinic 
03- Non govt health centre 
88-Other 
|__|__| 
2.8 For mobidity management 
have you got any training? 
00-No  
01-Yes 
|__|__| 
2.9 If yes, how did you find the 
content of your training for 
work? 
00-Inadequate 
01-Adequate 
03-Very detail 
 
|__|__| 
2.10  How was the duration of 
training? 
00-Very short 
01-short 
02-Appropriate 
03-seems longer than needed 
|__|__| 
2.11 Was there adequate hands 
on training? 
00-enough 
01-not at all 
02-more than requirement 
|__|__| 
2.12 Utilization of training in your 
work? 
00-very helpful 
01-helpful 
02-not helpful at all 
|__|__| 
2.13 Any suggestion regarding 
improvement of training? 
00-increase duration of training 
01-strenghtenng hands on training 
88- Other 
90- Don’t know 
|__|__| 
2.14 What measures are you using 
to manage their condition? 
Services No-
00 
Yes-
01 
Exercise regularly   
Soap washing   
Wearing sandals   
Keeping leg Clean and 
dry 
  
Bandages/Compressio
n with clothes 
  
Surgical (in case of 
testes swelling) 
  
Medicines   
 
 
2.15 What other measures do 
people practice other than 
your suggesion to get relief 
from health condition 
(filariasis)? 
00-Cutting with knife/fish bone 
01-Alternate/traditional herbal 
treatment 
02-Jhar-foak 
03-traditional method by “Oja” 
88-Other 
89-None 
|__|__| 
2.16 What are the services do you 
provide for Hydrocele? 
Services No-0 Yes-1 
Suggestion for 
operation 
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Care at home   
Follow up after 
surgery 
  
88-Other   
89- None   
 
2.17 Have you found the 
measures suggested by 
national programme, 
improved the condition of 
patient? 
00-No improvement 
01-Improvement 
02-Deteriorate the condition 
|__|__| 
2.18 If yes, what kind of relief does 
the patient get by practicing 
these measures? 
Improvements No-
00 
Yes-01 
Reduce pain   
Able to work for 
longer time 
  
Frequency of 
fever/ADL episodes 
decreases 
  
No foul smell from 
affected limb 
  
Feel better overall   
88-Other   
89- None   
 
 
    
2.19 How do you find caring for 
patients with advanced 
stages of disease? 
Experiences No-
00 
Yes
-01 
Difficult to move 
the affected limb, 
so cannot do 
exercise  
  
They can’t 
wash/dry by 
themselves in 
most cases. 
  
Improvement is 
slow. 
  
No improvement 
at all. 
  
88-Other…………   
 
 
2.20 How many patients have you 
helped with morbidity 
control during last 6 months? 
 
 
|__|__| 
2.21 How many times do you visit 
a patient in a month (on 
average) 
 
 
|__|__| 
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2.22 How much time could you 
spend for one patient on 
average? 
 |__|__| 
2.23 Do you think the allocated 
time for this patient is 
enough for services? 
00-No 
01- Yes 
|__|__| 
2.24 If Ans of 2.23 is no, What are 
the main cause of not giving 
enough time? 
00- You are too busy with other 
activities eg EPI 
01-It is not your prioritize work 
02-It is not seems to be helpful for 
patients  
03- Lack of awareness  
88-Other………………………….. 
89-.None 
|__|__| 
2.25 If you don’t provide services , 
from where they can get 
services 
0-Hospital 
1- NGO 
2-Friends or relatives 
88-Other 
|__|__| 
2.26 From where you get 
necessary supplies for 
providing care? 
00- from Govt/free 
01- Patients collect by themselves 
02- No supplies 
      88- other 
90-don’t know 
|__|__| 
2.27 What supports are provided 
by national LF elimination 
programme for patient? 
Supports No-
0 
Yes-1 
Distribution kit boxes 
containing brochure, 
soap, antibacterial 
/antifungal ointment, 
bandage, cloth etc 
  
Training for community 
service provider 
  
Training for supervisors   
88-Other……….   
 
|__|__| 
2.28 How helpful the kit box 
contents for patients  
0- Useful 
1- Not useful 
2- Patients don’t like 
3- They know the use of content 
of kit box 
4- Patient are able to buy  
88-other 
|__|__| 
 
 
 
2.29 What do you know about the 
prevention of diseases? 
Prevention No-0 Yes-1 
0-MDA   
1-Vaccination   
2-Prevention of 
mosquito bite 
  
88-Other……….   
89-Don’t know   
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2.30 When Mass Drug 
Administration (MDA) is 
conducted? 
00- November 
01-May 
02-Any time in the year 
88-Other 
90-Don’t know  
|__|__| 
2.31 Do you know how many 
times MDA is conducted in a 
year? 
00- one time 
01-two times 
02-no fix turn 
88- other 
90-don’t know 
|__|__| 
2.32 Which medicines are 
distributed during MDA 
00- 1 tab Albendazole & 1 tab DEC 
01- 1 tab Albendazole & DEC 1-3 tab 
according to age 
02- only DEC 
03- only Albendazole 
88- other 
90- don’t know 
|__|__| 
2.33 There is MDA for Filaria 
elimination every year. How 
do you participate in the 
programme? 
MDA activities No-
0 
Yes-1 
Administer drug in 
every house 
  
Supervise drug 
administration 
  
Conduct community 
awareness prior to 
drug administration 
  
Prepare report of 
drug administration 
  
88-Other……………….   
89- None   
 
 
2.34 Do the people take 
medication during MDA? 
00-very few people take medicines 
01-Most of the people take medicines 
02-Almost all take medicines 
 
2.35 If not taken medicine, what 
are the reasons for not taking 
the medicine? 
 
 
00- Absent at home during drug 
distribution 
01- Don’t know why they should take 
drug/ not explained by drug distributor 
02- lack of awareness 
03- Fear of side effects 
88-Other……………………….. 
89-.None 
|__|__| 
Now I will ask some questions where different people have different opinion. Please let us know 
your opinion. 
3.1 Filariasis is a not curable 
disease. 
00-completely agree 
01-partialy agree 
02-partialy disagree 
03-completely disagree 
90-Don’t know 
|__|__| 
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3.2 It can be prevented by 
vaccination. 
00-completely agree 
01-partialy agree 
02-partialy disagree 
03-completely disagree 
90-Don’t know 
|__|__| 
3.3 Elimination of Filariasis is 
possible. 
00-completely agree 
01-partialy agree 
02-partialy disagree 
03-completely disagree 
90-Don’t know 
|__|__| 
3.4 What are the problems you 
face during providing 
morbidity control? 
00-inadequate cooperation from 
patients 
01- Home based programme is difficult 
to follow up 
02-No adequate supplies of logistics 
03-People are not motivated about 
treatment 
04- lack of incentives for home based 
program 
88-Other………………………… 
89-None 
|__|__| 
3.5 What are your suggestion to 
overcome problems? 
00-Provide adequate supplies for 
patient 
01-Need incentive for service provider 
for home based service 
02- Need training 
03-Need awareness programme 
04- no incentive (career)  
88-Other …………………………… 
89-.None 
|__|__| 
 
Extra notes/comments:________________________________________________ 
 
 
Thank you very much for your cooperation 
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3.  School-based mass distributions of mebendazole to control soil-transmitted helminthiasis in the 
Munshiganj and Lakshmipur districts of Bangladesh: an evaluation of the treatment monitoring 
process and knowledge, attitudes, and practices of the population. 2015. Hafiz I, Berhan M, Keller A, 
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S, Hafiz I, Taylor M, Betts H, Mableson HE, Kelly-Hope L. (Plos NTDs - under review) 
